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General Introduction
Lung cancer is the number one cause of cancer death in the world, with an estimated 
1.8 million new diagnoses worldwide and 1.6 million deaths annually1. In 2016, 10,674 
deaths out of 148,997 total deaths in a population of around 17 million in the 
Netherlands were caused by lung cancer2. Symptoms usually occur when the cancer 
is in an advanced stage when treatment options are limited, hence it is no surprise 
that the 5-year survival rate for all stages combined in lung cancer is only 17%3. 
Detecting suspicious lesions in an early stage would considerably improve overall 
lung cancer survival. Lung cancers often start as a nodule. Based on imaging 
appearance, several nodule types are described and include solid nodules, perifissural 
nodules, and subsolid nodules.
 This thesis focuses on subsolid pulmonary nodules. Before the start of lung 
cancer screening trials, subsolid nodules were a relatively unknown and unrecognized 
entity among radiologists. Often described as focal infectious disease or simply 
missed on chest CT scans, subsolid nodules were not receiving much attention in the 
clinical setting. A few researchers speculated about the association between the 
adenocarcinoma spectrum and subsolid nodules in the early 1990s4,5. In 2002 
Henschke et al.6 confirmed the importance and dilemmas associated with subsolid 
nodules for the first time, based on results from one of the first lung cancer screening 
studies using CT. The authors discovered that although subsolid nodules were less 
frequently seen than solid nodules, the relative malignancy rate was considerably 
higher. These results marked a new era of research and the beginning of numerous 
publications about subsolid nodules, including this thesis.
What are subsolid nodules?
Pulmonary nodules are defined as “a rounded or irregular opacity, well or poorly 
defined, measuring up to 3 cm in diameter”7. Pulmonary nodules can be solid or 
subsolid, and either benign or malignant. The group of subsolid nodules is divided 
into two subcategories: nonsolid (synonym: pure ground-glass nodules) and 
part-solid (consisting of both a ground glass and a solid component, Figure 1). On 
a chest CT scan, ground-glass is defined as a focal area of slightly increased CT 
attenuation (‘hazy’) where the normal lung parenchyma, vessels and airways are 
still visible8. Solid, on the other hand, describes an area of increased attenuation 
that obscures underlying parenchymal architecture including vessels. Nodule 
attenuation correlates pathologically with the filling of the alveolar lumen and 
the thickness of the alveolar walls: complete filling with fluid and / or cells 
corresponds to the attenuation of solid, while incomplete filling and areas of 
remaining air cause ground glass attenuation9.
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Lung cancer screening
In 2010 the National Lung Screening Trial (NLST) released its results10. The NLST 
was a randomized controlled trial in the United States with 26,722 high-risk 
participants in the low-dose chest CT arm and 26,732 in the control group (chest 
X-Ray). The results showed, for the first time, that using low-dose CT as a screening 
tool lead to a relative lung cancer mortality reduction of 20% after 7 years of 
follow-up. Smaller randomized trials of low-dose chest CT screening have been 
conducted or are being conducted at this moment11–15. So far no other completed 
European trial has shown a significant decrease in mortality from lung cancer 
using CT as a screening tool.
 Irrespective of their final outcome, these screening trials have greatly 
contributed to our knowledge about subsolid nodules, most importantly with 
regards to frequency, persistence and malignancy risk. The percentage of 
screen-detected pulmonary nodules which are subsolid varies from 2% to 20% 
according to the literature6,16,17. The exact prevalence of incidental (clinical) 
subsolid nodules is not exactly known. However, several studies reported a lower 
mean general nodule prevalence of 13% for all types of incidental nodules, but 
with a comparable lung cancer prevalence to screen-detected nodules (1.5% and 
1.4% respectively)18. Thus, the vast majority of all nodule types is actually benign.
 The biggest challenge in either a screening or a clinical setting is to find the 
least invasive, most effective and accurate way to discriminate between potentially 
malignant and eventually benign nodules. This holds true for both solid and 
subsolid nodules. Current nodule management uses CT follow-up as a non-invasive 
tool to discriminate between growing or stable and between persistent or 
vanishing lesions.
Figure 1  CT images of the three subtypes of pulmonary nodules:  
(a) solid (b) partsolid and (c) nonsolid.
a b c
General Introduction | 13
This, however, involves costs and radiation dose, increases radiologists work - load 
and last but not least represents a various degree of psychological stress for the 
patient. Any increase in knowledge about the biological behavior of nodules and 
the correlation between nodule biology and imaging characteristics will therefore 
contribute to the optimization process of nodule management.
CT as imaging biomarker: what does that mean?
Around 40% of all diagnosed lung cancers represent adenocarcinomas19. The term 
adenocarcinomas refers to a group of histological subtypes with different 
biological behavior. Subsolid nodules have been shown to be precursors of a 
subgroup of adenocarcinomas (Figure 2)9,19. The latest IASCLC/ATS/ERS 2011 
classification of adenocarcinomas differentiate pre-invasive precursors such as 
atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS), from 
minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IA)8. 
These new guidelines marked the end of the term “bronchioloalveolar carcinoma” 
(BAC) that would correspond more or less to AIS and MIA according to the new 
classification.
Studies with radiological pathological correlation found a high association 
between CT morphology and histological subtype of invasiveness, proving that 
CT can be used as an “imaging biomarker”20–22. It is generally accepted that pre - 
invasive lesions correspond to pure ground glass lesions and a new or growing 
solid component correlates with the degree of invasiveness20. A solid component 
smaller than 6 mm in diameter has been adopted as a threshold to non-invasively 
differentiate between the likelihood of being a minimally invasive or an invasive 
adenocarcinoma23–25.
Figure 2  CT images of a part-solid nodule over time, developing into an invasive 
adenocarcinoma. Both the lesion and the solid core are showing growth.
a b c
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Persistent versus temporary subsolid nodules: role of morphology
The same way that solid nodules can have a benign character (e.g., hamartoma, 
granuloma), subsolid nodules can be benign or have a malignant potential. 
The differential diagnosis of benign subsolid nodules is long and includes 
focal fibrosis, focal bleeding or a granulomatous nodule within sarcoidosis or 
granulomatous vasculitis. Still, by far the most frequent benign reason for 
developing a subsolid nodule is a focal infection8,26. Infections are by definition 
temporary, thus longitudinal information over time (“does the lesion disappear?”) 
is the most effective and easiest way to securely exclude a potential malignancy.
Focal peribronchial infections - presenting as subsolid nodules - are a frequent 
finding for example in patients with chronic obstructive pulmonary disease 
(COPD) and chronic airways disease, thus a subgroup of patients with also an 
increased risk for developing a lung malignancy. According to the literature 38% 
- 70% of subsolid nodules turn out to be transient26–28. This wide range is related 
to the selection criteria and thus the composition of the study groups, but it 
illustrates the “size of the problem”.
 Morphologic features that would allow for prospective discrimination 
between transient (lesions that disappear over time, and are thus benign) and 
persistent (lesions that persist over time, might become malignant) subsolid 
nodules would be therefore of added value in improving nodule management. 
Examples of morphologic features used to describe solid nodules are spiculated 
(spikes on the surface of the nodule), lobulated (undulated contour of the border), 
or the definition of border sharpness. However, unlike their solid counterpart, 
subsolid nodules do not have well established morphologic features predictive of 
malignancy or persistence. Given the fact that earlier reports could show that not 
all persistent subsolid nodules necessarily develop into a malignancy and 
follow-up periods of several years are needed10, it would be especially beneficial 
to find features to discriminate between benign and malignant subsolid nodules.
What do current guidelines recommend for management of 
subsolid nodules?
There are several guidelines that guide the nodule management for a clinical and 
/ or screening setting. The most important are:
1. Guidelines by the Fleischner Society, an international, multidisciplinary 
medical society for thoracic radiology.
2. The Lung-RADS, developed by the American College of Radiology (ACR)
3. The British Thoracic Society (BTS) Guidelines
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The Fleischner Society Guidelines are intended for incidental nodules and were 
updated in 201725. Compared to the previous guidelines from 201329, the biggest 
change for subsolid nodules is the longer period before initial follow-up and 
increased total period of follow-up. The Fleischner Guidelines have adapted its 
guidelines to take into account the new knowledge that subsolid nodules grow 
slowly and thus need to be followed up for a longer period of time.
 At present the Fleischner Guidelines have the same size thresholds for the 
partsolid nodules as the Lung-RADS (2014). Lung-RADS is a categorical scoring 
system for chest CT scans and is intended for screen-detected nodules30. Both 
Lung-RADS and the Fleischner Guidelines advise for a more invasive workup if 
the nodule appears suspicious. For nonsolid nodules Lung-RADS defines a high 
threshold of 20 mm - larger than implemented in Fleischner - to trigger a yearly 
follow-up.
 Both, Fleischner and Lung-RADS allow for “exceptions of the rule” and recommend 
more intense work up, if the nodule is deemed to be suspicious by the radiologists. 
This procedure is more formalized in Lung-RADS: for nonsolid nodules > 20 mm 
and part-solid nodules ≥ 6 mm there is a special “category 4X” that warrants a 
more intense workup based on the radiologist’s subjective judgment: “category 3 
or 4 nodules with additional features or imaging findings that increases the suspicion 
of malignancy” may be upgraded to this category 4X.
 The British Thoracic Society released their new guidelines in 2015, intended 
for both clinical and screening use. Instead of size and nodule type based 
categories to recommend management, this is the only current guideline that 
includes a mathematical prediction model (further explained in next section) to 
assess risk of malignancy as a first instance. The guideline adapts management 
according to the individual nodule malignancy probability as determined by the 
prediction model18. In this guideline a few predefined suspicious morphologic 
features may lead to a more invasive management. A summary of the guidelines 
can be found in Table 1.
 Since there are differences in growth and malignancy rate between part-solid 
and nonsolid nodules, all guidelines make a distinction between the two nodule 
types in terms of nodule management. Most guidelines also distinguish between 
solid, part-solid and nonsolid nodules, and depending on size and presence of 
suspicious features, a different workup work is recommended for each type. 
Thus, the underlying classification of the type of nodule - as determined by visual 
assessment of the radiologist - is crucial for the workup recommendation.
 We know, however, from several studies that radiologists have a high inter- 
observer variability when it comes to nodule type classification. In this aspect, 
automatic classification of nodule types could be very advantageous. In the past 
few years, artificial intelligence systems based on deep learning algorithms have 
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Table 1   Summary of nodule management recommendations by three 
guidelines when a nodule is detected (at baseline / incidentally).
Nonsolid  
(pure ground-glass) nodule
Part-solid  
nodule
Fleischner Guidelines
< 6mm No routine follow-up No routine follow-up
≥ 6mm CT 6-12 months to confirm 
persistence, then CT every 
2 years until 5 years
• CT at 3-6 months.
• If unchanged and solid 
core remains < 6 mm: 
annual CT for 5 years
• solid core ≥ 6 mm: 
suspicious, thus more 
invasive follow-up
Multiple CT at 3-6 months to confirm 
persistence. If stable, 
consider CT at 2 and 4 years
CT at 3-6 months. 
Subsequent management 
based on most suspicious 
nodule(s).
Lung-RADS
< 20mm (Category 2) Low-dose CT at 12 months
≥ 20mm (Category 3) Low-dose CT at 6 months
< 6mm (Category 2) Low-dose CT at 12 months
≥ 6mm; solid core  
< 6 mm (Category 3)
Low-dose CT at 6 months
≥ 6mm; solid core  
≥ 6 mm to < 8 mm 
(Category 4A)
Low-dose CT at 3 months
≥ 8 mm solid core 
(Category 4B)  
category 3 or 4 nodules 
with findings that 
increase suspicion of 
malignancy  
(Category 4X)
Chest CT with or without 
contrast, PET/CT, biopsy
British Thoracic Society
< 5mm No routine follow-up
≥ 5mm CT at 3 months if no previous imaging,  
confirm persistence. Assess risk of malignancy using  
Brock model/morphology:
• Low risk (<10%): CT at 1, 2, 4 years
• High-risk (>10%) or concerning morphology  
(size of solid component in partsolid nodules,  
pleural indentation and bubble-like appearance):  
biopsy, treatment
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become a field of high interest in the medical world because of the significant 
performance improvement over classical machine learning systems. In our case, 
it might allow for an automatic detection and classification of nodules on CT, 
matching or eventually even surpassing the performance of experienced 
radiologists. This kind of system processes CT data containing a nodule, without 
the necessity of adding any additional information such as nodule features or 
nodule segmentation. Instead, the system learns by comparison with labeled 
examples (e.g. benign and malignant) through iterations of gradient descend 
based algorithms, instead of defining features beforehand31. It is likely that 
introducing such systems will standardize and improve the application of 
guidelines in clinical practice in the future.
Prediction models
Clinical prediction models can be used to assess the probability of malignancy in 
pulmonary nodules detected by CT. There are several known prediction models, 
which were developed on a relatively small population32–34. The first mathematical 
model (Brock model) that was developed using a large cohort of screening data 
was published in 2013 by McWilliams et al.17. Variables in the model include age, 
sex, family history of lung cancer, emphysema, nodule size, lobe location, nodule 
count and spiculation. The model was then validated on an external screening 
data set, and showed an excellent discrimination for the prediction of lung cancer 
in both development and validation data. Hence, various nodule management 
guidelines recommend this risk calculator as a tool to initially assess a nodule, 
both in a screening setting and clinical routine setting18,30. However, it is yet to be 
confirmed whether these model works equally well in a clinical routine 
population.
Thesis Outline
Nodule management largely depends on the associated malignancy risk: the 
more accurate the risk assessment, the more individualized and thus effective 
nodule management can be adapted. The goal of this thesis is therefore to gain 
more knowledge about the individual risk estimation of subsolid nodules.
 In part I (chapter 1 and 2) the focus lies on the radiologists’ visual assessment 
of morphological characteristics of screen-detected subsolid nodules. Are radiologists 
able to differentiate transient and persistent lesion character and correctly select 
high-risk nodules? Thirdly (chapter 3) we test whether the thresholds of lesion 
size as implemented in the current Lung-RADS, correctly reflect the malignancy 
risk for subsolid nodules in the lowest and the highest risk category.
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In part II (chapter 4 and 5) the focus lies on how mathematical prediction models 
and automatic classification can improve the management of subsolid nodules, 
but also nodules in general. Can we improve current logistic prediction models for a 
better prediction of malignancy rate in subsolid nodules? Can artificial intelligence 
play a role in the management of nodules by classifying nodule types?
 Last but not least in Part III (chapter 6), we focus whether the results found in 
screening studies, can be directly transferred to a clinical population and evaluate 
the Brock model - mathematically developed and evaluated using screening data - 
on a large heterogeneous clinical data set.
Part I: Visual assessment of subsolid nodule characteristics
In chapter 1 we take a step back from benign versus malignant and instead we 
investigate whether radiologists are able to conclude from CT morphology alone 
whether a subsolid nodule is persistent or transient and more specific, which 
morphologic features are used for this discrimination. Establishing morphologic 
features that reliably differentiate the transient from the persistent (and thus 
possibly malignant) nodules could be used to reduce the number of follow-up CT 
scan that have to be acquired.
 In chapter 2 we investigate whether Lung-RADS category 4X is of added value 
in the prediction of malignancy in subsolid nodules. As mentioned, category 4X is 
the so-called ’Fingerspitzengefühl’ category. But does it work? If radiologists 
upgrade many benign nodules into this category, many patients would undergo 
more unnecessary, more expensive or even invasive workup such as a PET scan or 
biopsy. Thus, we calculated the malignancy rate of upgraded 4X nodules, compared 
to the regular size-based categories.
 In chapter 3 we compare the possible underestimation of malignancy risk in 
the lowest size-based Lung-RADS category 2 versus the overestimation in the 
highest size-based category 4B. Nodules of category 2 are considered as having a 
“benign appearance or behavior” with a malignancy probability of < 1%. Though 
known for its indolent behavior of subsolid nodules, studies have shown that 
nonsolid nodules may actually represent invasive adenocarcinomas, especially 
when the lesion is larger than 10 mm35,36. At the other end of the risk spectrum 
category 4B represents the group with a malignancy probability of > 15%. Part-solid 
nodules ≥ 8 mm are categorized 4B. Lung-RADS does not contain a short-term 
follow-up to confirm persistence, thus making this category susceptible to 
overestimation because of the overlap with transient (infectious) nodules. In this 
chapter we investigate to which extent these two categories reflect the proper risk 
malignancy and appropriate management recommendations for subsolid nodules.
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Part II: Mathematical prediction models and automatic 
classification of subsolid nodules
In chapter 4 the Brock prediction model is specifically tested on subsolid nodules. 
As we know, in the Brock model development and validation data the majority of 
the nodule were solid. Since subsolid nodules have different characteristics 
compared to solid nodules, especially with regards to growth, we investigated 
whether the Brock model also has high discriminative power in subsolid nodules 
specifically. The second question was whether the accuracy of the Brock model 
could be improved by adding the longitudinal information of a second scan with 
respect to presence and extent of (short-term) nodule growth.
 In chapter 5 we investigate whether more advanced computerized systems 
can improve the classification of nodule type, mainly part-solid and nonsolid, 
solid and perifissural nodules. From literature we know that there is a high 
inter-reader variability when it comes to classifying nodule types37. However, 
current guidelines all make a distinction between nodule type in the management 
of nodules. Hence, it is an essential part of the nodule workup recommendations. 
In this chapter a deep learning based computer system is presented that can 
automatically classify all nodule types relevant to the nodule workup.
Part III: Risk prediction models for pulmonary nodules: transition 
from screening to clinical setting
Lastly, chapter 6 focusses on the clinical population. With the ever-growing 
number of CTs and improving software, more and more incidental pulmonary 
nodules are found on regular chest CT38. The Brock prediction model with external 
validation is recommended to be used as an initial risk estimator in the British 
Thoracic Society guidelines. However, the model has been developed on screening 
data. In this chapter we therefore focus on the Brock model and its validation on a 
much more heterogeneous clinical chest CT scan population with a range of 
possible comorbidities, which a radiologist would come across in his/her daily 
routine work.
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Abstract
Purpose: To evaluate whether, and to which extent, experienced radiologists are 
able to visually correctly differentiate transient from persistent subsolid nodules 
from a single CT examination alone and to determine CT morphological features 
to make this differentiation.
Materials and methods: We selected 86 transient and 135 persistent subsolid 
nodules from the National Lung Screening Trial (NLST) database. Four experienced 
radiologists visually assessed a predefined list of morphological features and gave 
a final judgment on a continuous scale (0-100). To assess observer performance, 
area under the receiver operating characteristic (ROC) curve was calculated. 
Statistical differences of morphological features between transient and persistent 
lesions were calculated using Chi-square. Inter-observer agreement of morphological 
features was evaluated by percentage agreement.
Results: Forty-nine lesions were excluded by at least 2 observers, leaving 172 
lesions for analysis. On average observers were able to differentiate transient 
from persistent subsolid nodules ≥ 10 mm with an area under the curve of 0.75 
(95% CI 0.67- 0.82). Nodule type, lesion margin, presence of a well-defined border, 
and pleural retraction showed significant differences between transient and 
persistent lesions in two observers. Average pair-wise percentage agreement for 
these features was 81%, 64%, 47% and 89% respectively. Agreement for other 
morphological features varied from 53% to 95%.
Conclusion: The visual capacity of experienced radiologists to differentiate 
persistent and transient subsolid nodules is moderate in subsolid nodules larger 
than 10 mm. Performance of the visual assessment of CT morphology alone is not 
sufficient to generally abandon a short-term follow-up for subsolid nodules.
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1
1.1  Introduction
Results of lung cancer screening Computed Tomography (CT) studies revealed the 
importance of subsolid nodules as potential early adenocarcinomas. In the Early 
Lung Cancer Action Project (ELCAP) study the prevalence of subsolid nodules 
was found to be lower compared to solid nodules. However, subsolid nodules 
demonstrated a higher malignancy rate of 34% (15/44) compared to 7% (14/189) for 
solid nodules6. Another study evaluating a group of clinically and screen-detected 
lesions even reported 81% (43/53) of resected subsolid nodules to be (pre)
malignant39.
 The most frequent benign disease causing subsolid nodules is a focal infection8,26. 
Other more rare underlying benign diseases are a focal organizing pneumonia or 
focal fibrosis40,41. Subsolid nodules caused by infection will eventually disappear. 
Differentiation of transience versus persistence of subsolid nodules thus represents 
the first diagnostic task to discriminate between benign and potentially malignant 
lesions, and a short-term three months follow-up has been recommended by the 
Fleischner Society and the British Thoracic Society18,29. The percentage of subsolid 
nodules detected in screening studies varied from 2% to 20% of all baseline 
screen-detected non-calcified nodules6,16,17. Prospective discrimination of transient 
from persistent lesions would therefore contribute to the reduction of follow-up CTs. 
Previous studies on this subject evaluated the contribution of texture analysis 
and clinical features but did not assess human observer performance27,28,42.
 The only other morphological feature used for risk prediction of subsolid 
nodules besides persistence and lesion growth, is nodule size and the presence/
size of a solid component17,30. For solid nodules spiculation is an important 
predictor of malignancy in a recently published (screening) risk model17. However, 
for subsolid nodules no additional morphological features have been established. 
Defining morphological features for transient and persistent subsolid nodules 
would be a valuable first step.
 The purpose of this study was therefore to evaluate whether and to which 
extent experienced radiologists would be able to differentiate transient from 
persistent subsolid nodules from a single CT examination alone by visual analysis. 
Secondly we aimed to identify which morphological features are used by the 
radiologists to make this differentiation.
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1.2  Materials and Methods
Study population
We recruited subsolid nodules from the National Lung Screening Trial (NLST). 
The NLST was approved by the institutional board at each participating 
medical institution and participants provided written informed consent before 
randomization43. In total, the NLST had 26,722 participants. Of those, 3194 
participants had at least one subsolid nodule annotated by the NLST screening 
radiologist in any of the 3 screening rounds. Nine participants did not have any 
scans available, leaving 3185 participants for further analysis.
 For this observer study, we used baseline (year 0) subsolid nodules only. 
The NLST annotations did not contain year-to-year linking between the same 
lesions, therefore we re-annotated all lesions by using information from the NLST 
database (slice number, nodule type, lobe location, size). Annotations were done 
by two medical students and one medical researcher using in-house software 
(CIRRUS Lung Screening, Diagnostic Image Analysis Group, Radboud University 
Medical Center, Nijmegen, the Netherlands). A subsolid nodule was defined as 
transient if the nodule had disappeared on follow-up CT. A subsolid nodule was 
defined as persistent if the nodule remained visible on follow-up CT.
 Subsequently, we only selected CTs with a slice thickness of ≤ 2 mm, to ensure 
the quality of the coronal and sagittal projections of the lesions. As morphology is 
more difficult to assess in smaller lesions and thicker slices, we only selected 
lesions ≥ 10 mm (rounded average diameter) in this observer study. In total 232 
subsolid lesions were eligible for our study. Eleven lesions (11/232, 4.7%) could not 
be located on the scans. Thus, our final database for the observer study contained 
221 subsolid lesions.
Observer study
All study lesions were independently evaluated by four experienced radiologists 
(ETS, CSP, MP, and JMG). All of them had > 15 years of experience in reading chest 
CTs and had extensive experience with evaluating screen-detected nodules. 
Nodules were presented in a random order to each observer. Observers were asked 
to score the morphological nodule features using a predefined list. The list of 
morphological features as well as the definitions can be found in Table 1.1. 
In addition, they were asked to estimate the probability that the lesion was 
persistent on a scale between 0 and 100, with 0 representing certainly transient 
and 100 representing certainly persistent.
 Transient or persistent | 25
1
Table 1.1   List of morphological features scored by each observer.  
For all features one category had to be chosen obligatorily.
Feature Possible categories Definition
Nodule type • nonsolid
• part-solid
• other
Nonsolid: hazy increased attenuation in the 
lung that does not obliterate the bronchial and 
vascular margins#
Part-solid: consists of both ground-glass and 
solid soft-tissue attenuation components#
Other: any other nodule type that is not a 
subsolid nodule (e.g. solid nodule, calcified 
nodule) or pseudo nodule (mimics a pulmonary 
nodule)#
Nodule 
multiplicity
• solitary
• multiple
Multiple nodular opacifications organized as  
a group within the same lobe
Lesion margin 
whole lesion
• ill-defined
• well-defined if 
welldefined, specify 
(only one option 
possible)
• linear demarcation
• lobulated
• spiculated
• smooth
Linear demarcation: following the lobular border 
Lobulated: undulated contour of the border 
Spiculated: with lines radiating from the borders
Smooth: a well-defined border which is not 
lobulated, spiculated or linearly demarcated
Solid core 
margin
• ill-defined
• well-defined  
if well-defined, 
specify (only one 
option possible)
• linear demarcation
• lobulated
• spiculated
• smooth
• multifocal
Multifocal: multiple spots of the solid core
Density of  
the ground-glass 
component
• low
• high
Low: faintly visible
High: substantially higher than lung 
parenchyma but still fulfilling the criteria of 
ground-glass
Aspect of  
the ground-glass 
component
• homogeneous
• inhomogeneous
With respect to density distribution
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Reading methodology
A reading workstation designed to optimize workflow and to document the 
scoring data was used (CIRRUS Observer, Diagnostic Image Analysis Group, 
Radboud University Medical Center, Nijmegen, the Netherlands). After opening a 
case, a magnified axial view of the nodule under evaluation was centered in the 
middle of the display. Coronal/sagittal projections were available on the right side of 
the screen (Figure 1.1). The position of the magnified view was indicated by center 
lines on the smaller views. Using this set-up, observers did not have to search for the 
lesion. For all cases, the full 3D CT dataset was available for evaluation. All views 
could be (de)magnified. A standard lung window with a width of 1500 HU and a 
center of -650 HU was used as a default but could be adjusted if necessary. Nodule 
diameters were measured manually using electronic calipers.
The morphological features to be scored were listed on the left side of the monitor 
display. Scoring had to be completed before the next lesion could be displayed. 
Observers were allowed to place any comments if needed. No specifications with 
respect to comments were made prospectively. Lesions indicated in the comments for 
exclusion by 2 or more observers were omitted for further analysis. No information 
about follow-up appearance, persistence or any other outcome was provided.
Table 1.1   List of morphological features scored by each observer.  
For all features one category had to be chosen obligatorily.
Feature Possible categories Definition
Air broncho-
gram
• no
• solitary
• multiple
Tubular air inclusions
Bubble lucency • no
• yes
Non-tubular air inclusions larger than 
neighboring bronchial structures
Pleural 
retraction
• no
• yes
Displacement of the interlobar fissure or pleura
External 
retraction 
of the lung 
parenchyma
• no
• yes
Distortion of the parenchymal architecture.  
This can be intranodular or extranodular, 
indicated by distortion of vessels or airways 
(signs of traction, displacement of neighboring 
bronchovascular structures)..
# definitions from the Fleischner Society: glossary of terms for thoracic imaging 7.
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Statistical Analysis
Receiver Operating Characteristic (ROC) analysis was performed for each observer. 
Areas under the curve (Az ) were calculated to determine the ability to differentiate 
between transient and persistent lesions. We did not take into account within 
participant correlation of participants with multiple nodules because multiple 
nodules in a participant were considered as multiple independent nodules44,45. 
Univariate analysis (Chi-square) per observer was used to assess whether a 
certain morphological feature was scored significantly different in transient or 
persistent nodules. P-values < 0.05 were considered significant. Inter-observer 
agreement for each CT morphological feature was investigated by calculating 
percentage agreement for each pair of observers. Statistical analyses were 
performed using SPSS, version 20.0 (SPSS, Chicago, Ill).
Figure 1.1  1 Reading workstation. The morphological features to be scored were 
listed on the left side of the monitor display. At the bottom there were two text 
fields to enter the probability (0-100) and any comments. A magnified axial view 
of the nodule under evaluation was centered in the middle of the display. Coronal/
sagittal projections were available on the right side of the screen, display size of 
the three projections was interchangeable. Processing tools such as windowing 
and magnification as well the full 3D CT dataset were available at any time.
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1.3  Results
Study group
Of all lesions 61% (135/221) were persistent. The median average diameter of 
persistent lesions was 12.0 mm (IQR 10.0 - 15.0 mm). Accordingly, 39% (86/221) 
were transient and had a median average diameter of 12.0 mm (IQR 11.0 - 16.5 mm). 
forty-nine lesions were excluded from further data analysis because at least 2 of 
the 4 observers had made the comment that the opacification under review, 
which had been marked as subsolid nodule in the NLST database, would in fact 
not represent a nodular (subsolid) opacification when taking all three planes into 
consideration. Comments leading to exclusion were not a nodule (N = 11), solid 
lesion (N = 8), wall of emphysema (N = 3), apical scarring, (N = 7), fibrosis (N = 5) 
and (plate-like) atelectasis (N = 15). Thus the final study group consisted of 172 
subsolid lesions (101 persistent, 71 transient).
Figure 1.2  Receiver Operating Characteristic (ROC) curves for observer 1, 2, 3 and 
4 to predict the persistence of the subsolid lesions ≥10 mm. Az (Areas Under the 
Curve) and 95% confidence interval in parenthesis, obs = observer.
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Discrimination of persistent from transient nodules
Observer 1 to 4 separately achieved an Az for discriminating persistent from 
transient subsolid nodules of 0.75 (95% CI 0.68-0.82), 0.75 (95% CI 0.67-0.82), 0.62 
(95% CI 0.53-0.70) and 0.69 (95% CI 0.60-0.77), respectively (Figure 1.2).
 Considering the score of 50 as a threshold for discriminating between transience 
(scores 0-50) and persistence (scores 51-100), the four observers correctly identified 
58/71 (82%), 63/71 (89%), 51/71 (72%) and 55/71 (77%) transient lesions. The observers 
correctly identified 52/101 (51%), 37/101 (37%), 47/101 (47%) and 61/101 (60%) 
persistent nodules, respectively.
 Taking the same thresholds for transience (0-50) and persistence (51-100), 
all four observers agreed on the same classification in 105 of the 172 nodules (61%). 
68 of these 105 nodules (65%) were correctly classified, and 37 of the 105 nodules 
(35%) were misclassified by all four observers. Thirty of the correctly classified 
nodules were persistent and 38 were transient. Figure 1.3 and 1.4 show examples 
Figure 1.3  (a) Correctly identified transient lesion with a probability score of ≤ 40 
by all four observers (b) Correctly identified persistent lesion with a probability 
score of ≥ 70 by all four observers (c) Incorrectly identified lesion by majority of 
observers: transient lesion, but scored as persistent (probability score ≥ 60) (d) 
Incorrectly identified lesion by majority of observers: persistent lesion, but scored 
as transient (probability score ≤ 40).
a
c
b
d
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of correctly and incorrectly identified lesions for which all or the majority of 
observers agreed on the classification.
Averaging the scores of the four observers resulted in an Az of 0.75 (95% CI 0.68- 
0.82) (Figure 1.5). Using the average scores a sensitivity of > 90% for persistent 
lesions was only achieved at the expense of a specificity of < 30% (e.g., sensitivity/
specificity is 91% / 28%).
Morphology assessment: univariate analysis
Morphological features that showed significant difference between transient and 
persistent in at least 2 observers are listed in table 1.2. At a significance level of p
< 0.05, nodule type and lesion margin were scored significantly different by 2 
observers (p = 0.016 and p = 0.025, p = 0.001 and p = 0.044 respectively). Part-solid 
nodules were more often seen in persistent lesions compared to transient lesions 
in all observers, reaching statistical significance in two of them. The subcategory 
of a well-defined border yielded significant difference in 2 observers (p < 0.001 and 
p < 0.001). Linear demarcation following the lobular border was the only feature 
in this category to be seen more often in transient lesions in three observers. 
Lobulated, spiculated and smooth borders were scored more often in persistent 
lesions. Pleural retraction was observed more frequently in persistent than 
transient lesions reaching significance in two observers (p = 0.006, p = 0.037).
Table 1.2: Table describes morphological features with at least 2 observers in 
which the feature is seen significantly different between transient (T) and 
persistent (P) subsolid nodules using Chi-square. The total number of included 
nodules after exclusion is 172.
Figure 1.4  (a) A transient lesion with disagreement (2 versus 2) among observers 
(b) A persistent lesion with disagreement (2 versus 2) among observers.
a b
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Inter-reader variability of morphology
Average pair-wise percentage agreement was highest in external retraction, 
pleural retraction and bubble lucency (95%, 89%, and 86% respectively). Nodule 
type had an agreement of 81%, followed by nodule multiplicity (73%), solid core 
margin (71%) and presence of an air-bronchogram (70%). Lower agreement was 
found in density of ground-glass component (67%), lesion margin (64%) and the 
subcategory of a well-defined solid core margin (62%). Lowest agreement was 
found for aspect of ground-glass component (53%) and the subcategory of a 
well-defined lesion margin (47%). The average pair-wise agreement and the 95% 
confidence intervals can be found in Table 1.3.
Figure 1.5  Receiver Operating Characteristic (ROC) curves for the average of all four 
observers. Az (Area Under the Curve) and 95% confidence interval in parenthesis.
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1.4  Discussion
The most frequent cause of transient subsolid nodules is a focal infection. A 
persistent subsolid nodule, however, is potentially malignant and requires 
follow-up or alternative diagnostic workup. A prospective estimation of whether 
the lesion would be persistent or transient would aid in reducing unnecessary 
follow-ups. This is the first study assessing the performance of human visual 
analysis for predicting the likelihood of persistence in subsolid nodules.
Results of our study indicate that experienced radiologists are at best only 
moderately able (average Az of all readings 0.75) to visually differentiate transient 
from persistent character in subsolid nodules ≥ 10 mm. In addition, the individual 
performance among the observers varied substantially with Az values ranging 
from 0.62 to 0.75. Given the variability among the observers, the moderate 
agreement and the imperfect performance of experienced radiologists, human 
visual analysis alone has to be considered insufficient to reproducibly predict if a 
subsolid nodule is persistent or transient. In that respect, our results confirm 
published management strategies18,29 that recommend a 3-month follow-up CT 
for clarification of persistence.
 A study by Lee HJ et al.46 evaluated the performance of radiologists predicting 
benign and malignant subsolid nodules, a differentiation that might be less 
complex, since persistent lesions can be both benign and malignant and the latter 
Table 1.3   Average pair-wise percentage agreement of the morphological 
features.
Morphological feature Agreement (%) 95% CI
Nodule type 81 79 - 84
Nodule multiplicity 73 61- 84
Lesion margin 64 56 - 71
Subcategory of well-defined margins 47 44 - 50
Solid core margin 71 67 - 75
Subcategory of well-defined solid core margins 62 59 - 65
Density of ground-glass component 67 64 - 69
Aspect of ground-glass component 53 45 - 61
Air bronchogram 70 59 - 82
Bubble lucency 86 82 - 89
Pleural retraction 89 86 - 92
External retraction 95 92 - 98
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may expose more suggestive features. However, even with the availability of 
several clinical parameters (age, sex, pack-years, history of lung cancer) and 
knowledge of predefined predictive CT information, an average Az value of 0.77 for 
nonsolid and of 0.76 for part-solid nodules were achieved, thus in fact comparable 
to our results.
 Secondly, we found that none of the morphology features yielded significant 
discrimination in all four observers. Most promising features were nodule type, 
lesion margin, presence of a well-defined lesion margin and pleural traction. The 
average pair-wise percentage agreement was relatively high in nodule type and 
pleural retraction (81% and 89% respectively). A considerably lower agreement, 
however, was found for features that had to be rated qualitatively such as lesion 
margin in general or the subcategory of a well-defined lesion margin (63% and 
47%, respectively), indicating that these features do not appear to be sufficiently 
definable by visual analysis to serve as a broadly applicable criterion within a 
screening process.
 Interestingly, however, when looking at the subcategory of a well-defined 
border, three observers scored linearly demarcated border more frequently in 
transient lesions (27/40, 18/27, and 23/39) compared to persistent lesions. We did 
not prospectively define whether the linear demarcation following the lobular 
border had to be present in several projections, which most likely contributed to 
the fact that one observer scored the feature only 4 times. The finding of linear 
demarcation shows similarity with a finding reported by Felix et al.27. Their study 
described a polygonal shape (defined “as a lesion with linear or concave margins 
at every corner”) as indicative for a transient lesion. Furthermore, they found that 
transient subsolid nodules were more frequently lobulated than persistent 
nodules. The finding of lobulation being predictive for transience reported by 
Felix et al.27 is in contradiction to the other study by Lee SM et al.28, who reported 
lobulation as indicative for malignancy. Similarly, we found that 74% to 100% of 
the lobulated lesions were found to be persistent (15/16, 28/36, 1/1, 20/27 
respectively).
 In this study, we selected the subsolid nodules following the nodule type 
annotations of the NLST database. Previous studies have shown that the agreement 
among radiologists is only moderate with regards to the  differentiation of 
part-solid, nonsolid and solid nodules37,47. Therefore we decided to exclude all 
lesions that were considered not a subsolid nodule by at least 2 of the 4 observers. 
We did so, to increase accuracy and reliability of the observer data.
 Our study has limitations. First, our study did not include any elaborate 
texture or quantitative analysis. Visual CT features in combination with elaborate 
objectively quantifiable measures might not only improve performance but also 
achieve a higher reproducibility. Second, we selected lesions ≥ 10 mm only, taking 
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into account the fact that the majority of the NLST CTs has not been reconstructed 
with 1 mm slice thickness, thus not providing isotropic high-resolution image 
quality in all three projections. The level of performance and reader agreement 
we found, confirms the notion that visual assessment of morphological features 
in lesions < 10mm will be even more difficult and less reliable. Last, the CT 
examinations of the NLST trial have been obtained with different scanners and 
variable slice thickness. Though only scans with a slice thickness of ≤ 2 mm were 
included, the diverging image quality might have influenced the visual 
assessment of the nodules.
In conclusion, experienced radiologists are moderately able to visually determine 
persistent and transient nodule character in lesions ≥ 10 mm. There are 
morphological features indicative for the discrimination of persistent and 
transient nodules, but none of them yielded significant discrimination in all four 
observers. Our results show that performance of the visual assessment of CT 
morphology alone is not sufficient to generally abandon a short-term follow-up 
and inter-reader variability plays a substantial role even among highly 
experienced observers.

Lung-RADS 4X
K. Chung, C. Jacobs, E.T. Scholten, J.M. Goo, H. Prosch, N. Sverzellati, F. Ciompi,
O.M. Mets, P.K. Gerke, M. Prokop, B. van Ginneken, C.M. Schaefer-Prokop
Original title: Lung-RADS Category 4X: Does It Improve Prediction of  
Malignancy in Subsolid Nodules?
Published in: Radiology 2017 284(1):264-271
2
38 | Chapter 2
Abstract
Purpose: To evaluate the added value of Lung CT Screening Reporting and Data 
System (Lung-RADS) assessment category 4X over categories 3, 4A, and 4B for 
 differentiating between benign and malignant subsolid nodules (SSNs).
Materials and methods: SSNs on all baseline computed tomographic (CT) scans 
from the National Lung Cancer Trial that would have been classified as Lung- 
RADS category 3 or higher were identified, resulting in 374 SSNs for analysis. 
An experienced screening radiologist volumetrically segmented all solid cores 
and located all malignant SSNs visible on baseline scans. Six experienced chest 
radiologists independently determined which nodules to upgrade to category 4X, 
a recently introduced category for lesions that demonstrate additional features or 
imaging findings that increase the suspicion of malignancy. Malignancy rates of 
purely size-based categories and category 4X were compared. Furthermore, the 
false-positive rates of category 4X lesions were calculated and observer variability 
was assessed by using Fleiss κ statistics.
Results: The observers upgraded 15% - 24% of the SSNs to category 4X. The 
malignancy rate for 4X nodules varied from 46% to 57% per observer and was 
substantially higher than the malignancy rates of categories 3, 4A, and 4B SSNs 
without observer intervention (9%, 19%, and 23%, respectively). On average, the 
false-positive rate for category 4X nodules was 7% for category 3 SSNs, 7% for 
category 4A SSNs, and 19% for category 4B SSNs. Of the falsely upgraded benign 
lesions, on average 27% were transient. The agreement among the observers was 
moderate, with an average κ value of 0.535 (95% confidence interval: 0.509, 0.561).
Conclusion: The inclusion of a 4X assessment category for lesions suspicious for 
malignancy in a nodule management tool is of added value and results in high 
malignancy rates in the hands of experienced radiologists. Proof of the transient 
character of category 4X lesions at short-term follow-up could avoid unnecessary 
invasive management.
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2.1  Introduction
Current guidelines and recommendations for the management of screen-detected 
pulmonary nodules mainly depend on nodule type-specific diameter thresholds 
and the presence of growth18,30,48. The nodule type helps differentiate between 
solid nodules and subsolid nodules (SSNs). The latter are further subdivided into 
nonsolid or part solid, depending on the presence of a solid component. Two recent 
publications reported a high variability among radiologists in classifying nodules 
as subsolid, mainly because of disagreement on the presence or size of a solid 
component37,47. This is of specific importance because SSNs potentially manifest as 
early adenocarcinomas, with the size of the solid component having an important 
correlation to the histologic characteristics of invasive adenocarcinomas9,20.
 In 2014, the American College of Radiology published the Lung CT Screening 
Reporting and Data System (Lung-RADS), a categorical scoring system for 
screening- detected nodules with various management steps adapted to the 
malignancy risk of the nodule. In addition to nodule type and diameter, growth 
over time plays an important role in classification. The risk of malignancy grows 
as the nodule category increases from 1 to 4X. Lung-RADS introduced a category 
4X for lesions that demonstrate “additional features or imaging findings that 
increase the suspicion of malignancy”.
 According to Lung-RADS, upgrading a nodule to category 4X is possible only 
for category 3, 4A, or 4B nodules. This upgrade triggers a more intensive diagnostic 
workup ranging from short-term clinical follow-up computed tomography (CT) to 
more advanced diagnostic procedures (eg, positron emission tomography) or 
invasive procedures, including biopsy and resection30. Although morphologic 
criteria used to differentiate between benign and malignant findings are 
reasonably well established for solid nodules, these criteria are still evolving for 
SSNs22,35,46,49,50. A morphologically triggered category 4X would therefore involve 
issues that are still unresolved for SSNs.
 To our knowledge, the degree to which the addition of category 4X improves 
the performance of Lung-RADS for predicting the probability of malignancy of 
an SSN has not been demonstrated. The purpose of our study was to evaluate 
the added value of Lung-RADS category 4X over categories 3, 4A, and 4B in the 
differentiation between benign and malignant SSNs.
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2.2  Materials and methods
Study Group and Nodule Annotations
We analyzed all CT scans of the chest from the National Lung Screening Trial 
(NLST)10 in which at least one SSN was annotated by the NLST screening 
radiologist. The CT arm of the NLST consisted of 26722 subjects, 3194 of whom had 
at least one SSN in any screening round according to the NLST reading database. 
CT data were incomplete for nine subjects according to the NLST, leaving 3185 
subjects for further analysis. A comprehensive description of study design and CT 
technique has been published previously51. The NLST was approved by the 
institutional board at each participating medical institution. All participants 
provided written informed consent before randomization.
 The NLST database provided the following information for all screening- 
positive nodules (ie, 4 ≥ mm diameter): section number and lobe in which the 
nodule was found, long and perpendicular diameter of the nodule, and nodule 
type. Lung cancer diagnoses were reported in participants with positive nodules 
during a median follow-up of 6.5 years (maximum, 7.4 years), including the time 
of diagnosis10. However, the NLST provided no data about which nodule developed 
into lung cancer. Moreover, the size of solid cores in part-solid nodules was not 
available.
 The first step in our study was to identify the SSNs on annotated scans from 
the NLST by matching lesions in the affected lobe with size, section number, and 
nodule type recorded during screening. This was done by trained medical students 
and a medical researcher using dedicated in-house software (CIRRUS Lung 
Screening; Diagnostic Image Analysis Group, Nijmegen, the Netherlands) that 
included computer-aided detection and semiautomatic volumetry. A nodule listed 
in the NLST database but not identifiable on the numbered section from the 
annotated lobe was marked as not found. All solid cores were reevaluated and 
segmented by a radiologist (E.T.S.) with more than 5 years of experience in reading 
screening CT scans of the chest.
 The same radiologist identified the malignant nodules by using NLST 
database information with respect to the tumor-bearing lobe, year of diagnosis, 
and tumor size at pathologic examination. Probability scores were used to classify 
the degree of certainty in this identification process on a scale of 0 to 3, where 3 
indicates very high certainty (lesion was located in the tumor-bearing lobe on a 
scan obtained within 1 year of tumor diagnosis), 2 indicates high certainty (the 
lesion was located in the tumor-bearing lobe and imaging signs were suggestive 
of malignancy; however, the diagnosis of malignancy was made more than 1 year 
from the last available screening image), 1 indicates low certainty (lesion was 
located in the tumor-bearing lobe and could potentially develop into a malignancy 
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over time but the diagnosis was made more than 1 year from the last available 
screening CT scan and available images did not reveal unequivocal signs of 
malignancy), and 0 indicates very low certainty (no lesion was visible) (Table 2.1). 
Imaging signs suggestive of malignancy included growth over time and spiculation. 
For this study, only malignant lesions with probability scores of 2 and 3 were 
considered as being visible at baseline.
Study Population
At baseline CT, 1807 nonsolid nodules and 510 part-solid nodules had been reported 
by NLST readers. Use of at least Lung-RADS category 3 as an inclusion criterion 
resulted in a study group of 47 nonsolid and 348 part-solid lesions. Retrospective 
identification of the nodule on the scan was possible in 43 of the 47 (91%) nonsolid 
nodules and 331 of the 348 (95%) part-solid nodules. Reasons for failure of 
identification were incomplete Digital Imaging and Communications in Medicine 
data for the scan (n = 11) or the fact that no nodule could be found by using the 
anatomic information provided by the NLST (n = 10). This left a total of 374 lesions 
available for analysis.
 Of the 374 lesions assigned a probability score of 2 or 3 by the expert radiologist, 
56 SSNs were considered malignant. Of these 56 SSNs, 49 (88%) were diagnosed as 
cancers in year 0, 1, or 2 with an available scan of diagnosis and thus were given a 
score of 3. The remaining seven SSNs (13%) were diagnosed after the screening 
rounds (in year 3 to year 6) and were given a score of 2. Six of these seven lesions 
Table 2.1   Probability scores used to determine level of certainty for  
malignant lesions.
Probability 
score
Definition
0 (very low) No lesion visible in the tumor-bearing lobe
1 (low) Lesion located in the tumor-bearing lobe that could potentially 
develop into a malignancy over time, but diagnosis was made 
more than 1 year from the last available screening CT scans and 
available images did not reveal unequivocal signs of malignancy
2 (high) Lesion located in the tumor-bearing lobe and imaging signs very 
suggestive of malignancy; however, diagnosis of malignancy was 
made more than 1 year from the last available screening scan
3 (very high) Lesion was located in the tumor-bearing lobe on a
scan obtained within 1 year of tumor diagnosis
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showed an increase in nodule mass over time on the screening CT scans; no 
followup scan was available for the remaining nodule to confirm growth, but the 
nodule demonstrated highly suspicious signs such as spiculation as assessed by 
consensus of two expert radiologists. No nodule was attributed a score of 1. Two 
participants were attributed a score of 0.
Observer Study
We selected SSNs that would have been classified as Lung-RADS category 3 or 
higher, meaning nonsolid nodules measuring at least 20 mm and part-solid 
nodules measuring at least 6 mm. Original NLST annotations for nodule types 
and nodule size were used. For the solid core, the diameter measurement from the 
experienced radiologist was used. We presented the set of selected nodules to six 
radiologists (E.T.S., J.M.G., H.P., N.S., M.P., and C.M.S.), all with at least 15 years of 
experience in reading chest CT scans and extensive experience in reading 
screening CT scans. A reading workstation to optimize workflow and to document 
scoring data was used (CIRRUS Observer, Diagnostic Image Analysis Group). 
When a case was opened, a magnified axial view of the nodule was displayed. 
Coronal and sagittal projections were available but were often of suboptimal 
quality because most scans were reconstructed with 2.5-mm-thick sections. The 
full three-dimensional CT scan with different window settings was available to 
the readers at any time. For each nodule, the observers were asked whether they 
would classify the nodule as category 4X. If the answer was yes, the reader was 
asked which imaging features increased the suspicion of malignancy to justify 
the use of category 4X.
 The readers classified the imaging features as present or absent. The following 
imaging features were evaluated: features that referred to the effect on surrounding 
tissue (defined as retraction, displacement of fissure, overinflation), internal 
nodule structure (defined as high and/or inhomogeneous attenuation), border 
characteristics (defined as spiculation, sharp or unsharp definition, lobulation), 
presence of bullae (defined as dilated bronchi and/or air inclusions), and solid core 
characteristics (defined as spiculated, multifocal).
Statistical Analysis
Statistical analyses were performed by using software (SPSS, version 20.0; SPSS, 
Chicago, Ill). Interobserver agreement was assessed by using Fleiss κ statistics. 
Malignancy rates -defined as the percentage of malignant lesions in all lesions 
per categorywere calculated for the original categories (categories 3, 4A, 4B) and 
for category 4X. The false-positive rate was calculated for each observer to 
quantify how many benign nodules were incorrectly upgraded to a higher risk 
category. The Fisher exact test was used to assess whether there was a statistically 
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significant difference in scores assigned to morphologic features in benign and 
malignant lesions that were upgraded to category 4X.
2.3  Results
Malignancy Rates without and with Use of Category 4X
The malignancy rates of nodules classified purely according to size (ie, without 
taking category 4X into account) were 9% (17 of 196 nodules) for category 3 SSNs, 
19% (11 of 58 nodules) for category 4A SSNs, and 23% (28 of 120 nodules) for category 
4B SSNs. On average, the observers upgraded 18% (95% confidence interval [CI]: 
15%, 22%) of the 374 nodules to category 4X. The agreement among the observers 
was moderate, with an average κ value of 0.535 (95% CI: 0.509, 0.561). Figures 2.1 
and 2.2 show examples of nodules for which there was agreement and 
disagreement among the observers.
Malignancy rates -calculated separately for lesions upgraded and not upgraded to 
category 4X- are listed per observer in Table 2.2. Malignancy rates of category 4X 
nodules varied from 46% to 57% for the six observers, with an average of 53% (95% 
CI: 49%, 56%). The malignancy rates of category 4X nodules exceeded 50% for all 
but one observer. For all six observers, the malignancy rate for category 4X nodules 
was substantially higher than that for the purely size-based Lung-RADS categories 
alone (9%, 19%, and 23% for Lung-RADS categories 3, 4A, and 4B, respectively) 
(Table 2.2). After some nodules were upgraded to category 4X, the average 
malignancy rates in the remaining nonupgraded nodules decreased to 4% (95% 
CI: 3%, 5%) for category 2 nodules, 10% (95% CI: 6%, 15%) for category 4A nodules, 
and 10% (95% CI: 8%, 12%) for category 4B nodules.
Figure 2.1  CT scans show malignant SSNs correctly upgraded by all six observers.
a b c
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In total, 96% of the malignancies diagnosed at baseline (27 of 28 nodules) were 
correctly upgraded by at least one of the six observers. During follow-up, the 
corresponding number was 82% (23 of 28 nodules). The average percentage of 
correctly upgraded lesions was highest in category 4A, with 65% (95% CI: 55%, 
74%). An average of 46% (95% CI: 40%, 52%) of nodules in category 3 and 54% (95% 
CI: 50%, 58%) in category 4B were correctly upgraded (Table 2.3).
False-Positive Upgrade of Benign Nodules to Category 4X
The average false-positive rate was 7% (95% CI: 5%, 9%) for category 3 nodules, 7%
(95% CI: 4%, 10%) for category 4A nodules, and 19% (95% CI: 13%, 24%) for category 
4B nodules. Of the benign and thus falsely upgraded lesions, an average of 27% 
(95%CI: 18%, 36%) were transient. The average percentage of falsely upgraded 
Figure 2.2  Example CT scans of SSNs for which upgrade to category 4X was 
determined variably by the six observers. (a) Malignant lesion upgraded by  
three observers. (b) Malignant lesion upgraded by four observers. (c) Benign 
lesion upgraded by two observers. (d) Benign lesion upgraded by three observers. 
(e) Benign lesion upgraded by four observers. (f) Benign lesion upgraded by  
four observers.
a
d
b
e
c
f
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transient nodules was 36% (95% CI: 19%, 54%) for category 3 nodules, 4% (95% CI: 
0%, 15%) for category 4A nodules, and 25% (95% CI: 14%, 36%) for category 4B 
nodules.
Table 2.2   Malignancy rates for nonupgraded subsolid nodules and  
those upgraded to category 4X.
Variable Lung-RADS 3 Lung-RADS 4A Lung-RADS 4B Lung-RADS 4X
Size-based Lung-RADS 17/196 (9) 11/58 (19) 28/120 (23) ...
Observer 1 9/178 (5) 9/55 (16) 8/83 (10) 30/58 (52)
Observer 2 3/168 (2) 3/46 (7) 8/86 (9) 42/74 (57)
Observer 3 7/177 (4) 5/48 (10) 9/85 (11) 35/64 (55)
Observer 4 8/177 (5) 7/50 (14) 12/92 (13) 29/55 (53)
Observer 5 6/166 (4) 3/46 (7) 5/71 (7) 42/91 (46)
Observer 6 9/177 (5) 4/49 (8) 8/82 (10) 35/66 (53)
Average (%)* 4 (3, 5) 10 (6, 15). 10 (8, 12) 53 (49, 56)
Note: Malignancy rates were determined as follows: number of malignant nodules/total number of 
nodules in Lung-RADS category X 100. A total of 374 nodules were analyzed, of which 56 were 
malignant. Except where indicated, data are numbers  of nodules, with percentages in parentheses. 
* Data in parentheses are 95% CIs. Average is average of observers.
Table 2.3   Malignancy rates for lesions upgraded to category 4X.
Observer Total Upgraded to 
Category 4X
Upgraded from 
Lung-RADS 3
Upgraded from 
Lung-RADS 4A
Upgraded from 
Lung-RADS 4B
1 30/58 (52) 8/18 (44) 2/3 (67) 20/37 (54)
2 42/74 (57) 14/28 (50) 8/12 (67) 20/34 (59)
3 35/64 (55) 10/19 (53) 6/10 (60) 19/35 (54)
4 29/55 (53) 9/19 (47) 4/8 (50) 16/28 (57)
5 42/91 (46) 11/30 (37) 8/12 (67) 23/49 (47)
6 35/66 (53) 8/19 (42) 7/9 (78) 20/38 (53)
Average (%)* 53 (49, 56) 46 (40, 52). 65 (55, 74) 54 (50, 58)
Note: Malignancy rates were determined as follows: number of malignant nodules/total number of 
upgraded nodules X 100. Except where indicated, data are numbers of nodules, with percentages in 
parentheses. * Data in parentheses are 95% CIs.
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Morphologic Characteristics
Internal structure was the most common imaging feature considered to be 
suspicious (average, 44 findings; 95% CI: 28, 59), followed by border characteristics 
(average, 43 findings; 95% CI: 28, 58). Solid core characteristics were the least 
common feature considered to be suspicious (average, 19 findings; 95% CI: 5, 32). 
Effect on surrounding tissue and bullae were considered suspicious in an average 
of 23 (95% CI: 15, 31) and 20 (95% CI: 10, 29) cases, respectively.
None of the features showed a statistically significant difference by all six 
observers between falsely upgraded benign and correctly upgraded malignant 
4X lesions. Only border characteristics (P = .016 for observer 2 and P = .019 for 
observer 6), internal structure (P = .018 for observer 2), and solid core (P = .046 for 
observer 5) were rated with a significantly greater frequency in malignant nodules 
(Table 2.4).
2.4  Discussion
Lung-RADS is the only scoring system that proposes an extra category 4X, which 
allows the observer to upgrade a nodule to a higher risk category if the observer 
considers the nodule more suspicious. Thus, category 4X introduces a subjective 
component into the nodule management process but also offers a possibility to 
increase the efficiency of the screening process. In our study, 15%-24% of SSNs 
were upgraded to category 4X. The malignancy rate for category 4X nodules per 
observer varied from 46% to 57%, which was substantially higher than those 
for purely size-based categories 3, 4A, and 4B (9%, 19%, and 23%, respectively). 
The results of our study therefore indicate that the inclusion of a 4X category 
for suspicious lesions in a nodule management tool provides substantial added 
value and results in high malignancy rates in category 4X SSNs.
 Furthermore, the successful true positive selection of malignant 4X lesions 
shows that there are morphologic features other than size and nodule type that 
enable the correct classification of malignant lesions. Previous studies have 
reported that a lobulated or spiculated border, solid core size, and nodule size 
enable the prediction of malignancy in SSNs35,46. In our study, observers were 
asked to specify morphologic features only for nodules classified as category 4X. 
Therefore, we cannot draw conclusions as to whether these morphologic features 
enable differentiation between benign and malignant lesions; rather, the fact 
that (almost) no significant differences in morphologic criteria were seen between 
true and false-positive 4X lesions emphasizes the overlap of certain morphologic 
features if visually assessed. In addition, the agreement among radiologists as to 
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which SSN should be upgraded was only moderate, underlining the subjective 
character of such a selection process. Observers were successful at increasing the 
malignancy rate in category 4X to approximately 50%, but they used different 
morphologic criteria to select their cases. This suggests that it may be difficult to 
establish suspicious morphologic features. The fact that at least one observer 
upgraded a malignant SSN to category 4X in 96% of malignancies diagnosed at 
baseline and 82% of malignancies diagnosed at follow-up suggests that there are 
morphologic features that may help differentiate benign from malignant nodules 
by means of computer analysis that goes beyond the capabilities of experienced 
human observers52–54.
 Our results also showed that such a subjective, purely visual tool resulted in 
an upgrade of benign lesions that would have unnecessarily undergone a more 
intense work-up, including biopsy or resection. A frequent benign counterpart of 
SSNs is focal infections that are transient in nature26,55. A number of studies have 
addressed the capability of differentiating transient from persistent lesions on 
the basis of morphologic features27,28,42. Because none of these visual or 
computerized tools yielded a perfect discrimination, the approach proposed by 
the Fleischner Society guidelines seems to be the most effective. These guidelines 
propose short-term follow-up after 3 months to assess persistence of SSNs29. The 
fact that an average of 27% of the incorrectly upgraded benign lesions in our study 
group turned out to be transient underlines the importance of such a follow-up 
tool. Lung-RADS categories 4X and 4B trigger a wide variety of management tools, 
ranging from CT follow-up with diagnostic quality (approximating the short-term 
follow-up suggested by the Fleischner Society) to biopsy or resection. Given the 
interobserver variability, it seems advisable in general to include a noninvasive 
short-term CT follow-up examination of 4X nodules if persistence has not been 
proven, before invasive procedures are initiated.
 On average, the highest size-based malignancy rate was found in category 4B 
nodules. Although category 4B lesions are allowed to be upgraded, currently the 
recommendations for management are the same for categories 4B and 4X. 
In Lung-RADS, an estimated malignancy rate of greater than 15% is given for 
category 4B nodules. However, in our study we found an average malignancy rate 
of 10% among the observers for nonupgraded SSNs in category 4B. For nonupgraded 
category 3 and 4A SSNs, the average malignancy rates (4% [estimated malignancy 
rate with Lung-RADS, 1%-2%] and 10% [estimated malignancy rate with 
Lung-RADS, 5%- 15%], respectively) were generally in line with the Lung-RADS 
malignancy rates, taking also into account that Lung-RADS malignancy rates 
have been formulated for all nodule types. Thus, without the growth criteria and 
considering only size, category 4A and 4B SSNs do not differ substantially in 
malignancy risk and may be summarized into one category for SSNs once 
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persistence has been confirmed and more suspicious lesions have been upgraded 
to category 4X. Category 4X SSNs, conversely, have a malignancy rate of 
approximately 50%, which far exceeds the 15% risk cutoff given in Lung-RADS. 
This malignancy rate increases even further to more than 60% if 3-month 
follow-up is performed and shrinking nodules are excluded. As a consequence, a 
more aggressive diagnostic work-up seems to be justified for category 4X SSNs.
 Our study specifically focused on SSNs because the morphologic spectrum of 
SSNs is very variable and much broader than that of solid lesions35,46,56. We 
therefore expected more opportunities, but also a higher variability, for applying 
category 4X in SSNs than in solid nodules. It can be critically discussed whether 
intensified nodule management is needed for SSNs, which in general have more 
indolent biologic behavior and much slower growth9. Some investigators have 
reported that patient outcome is not affected if such lesions undergo follow-up at 
longer intervals and if treatment is undertaken only if unequivocal lesion growth 
is documented57–59. This also means that the set of nodules considered benign in 
our analysis may include slow-growing lesions such as occult adenocarcinoma in 
situ or minimally invasive adenocarcinoma because not all nodules were resected 
during the median follow-up of 6.5 years. An argument in favor of earlier differen-
tiation of SSNs is that multiple long-term CT follow-up may be avoided, which 
decreases cost, anxiety, and radiation exposure.
 Our study has limitations. First, we did not ask the radiologists to follow the 
entire Lung-RADS procedure, which would have meant measuring the nodule, 
assigning nodule type, and categorizing the nodule. However, from previous 
studies we know that there is high interreader variability among radiologists 
with regard to the assignment of nodule type37,47. To avoid this interreader 
variability, we chose to select nodules applicable for an upgrade to 4X by using 
NLST nodule annotations and only to ask the observers whether they would 
upgrade the nodule to category 4X. Second, morphologic features were scored 
only in upgraded 4X lesions; thus, a multivariate analysis with regard to benign 
and malignant nodule morphologic characteristics was not possible. Third, our 
six observers were experienced radiologists. This further underlines the 
subjectivity of such a visual selection process. Because eligibility for category 4X 
was based on the radiologist’s judgment, there was no specific training for the 
radiologists to standardize the observers’ opinions. We developed a four-point 
confidence score for localizing the malignancies, taking all anatomic and 
follow-up information into consideration. Although only nodules with high 
confidence scores were included in this study, this procedure leaves a small but 
existing uncertainty. Last, the most recent International Association for the Study 
of Lung Cancer/American Thoracic Society/European Respiratory Society 
classification had not been applied when the NLST trial was carried out, meaning 
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that it is unknown how many of the lesions included as T1 malignancies in the 
NLST database were actually minimally invasive adenocarcinomas.
 In conclusion, our results indicate that the application of category 4X for 
suspicious SSNs is of substantial added value in the Lung-RADS system, with very 
high malignancy rates in the hands of experienced radiologists. Proof of the 
transient character of lesions in category 4X at short-term follow-up could avoid 
unnecessary invasive management.
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Abstract
Purpose: Lung-RADS proposes malignancy probabilities for categories 2 (<1%) and 
4B (>15%). The purpose of this study was to quantify and compare malignancy 
rates for Lung-RADS 2 and 4B subsolid nodules (SSNs) on a nodule base.
Methods: We identified all baseline SSNs eligible for Lung-RADS 2 and 4B in the 
National Lung Screening Trial (NLST) database. Solid cores and nodule locations 
were annotated using in-house software. Malignant SSNs were identified by an 
experienced radiologist using NLST information. Malignancy rates and percentages 
of persistence were calculated.
Results: Of the Lung-RADS 2 SSNs, 94.3% (1790/1897) could be located on chest CTs. 
Likewise, 95.1% (331/348) of part-solid nodules ≥ 6 mm in diameter could be located. 
Of these, 120 had a solid core ≥ 8 mm, corresponding to category 4B. Category 2 
SSNs showed a malignancy rate of 2.5%, exceeding slightly the proposed rate of 
<1%. Category 4B SSNs showed a malignancy rate of 23.9%. In both categories 
one-third of benign lesions were transient.
Conclusion: Malignancy probabilities for Lung-RADS 2 and 4B generally match 
malignancy rates in SSNs. An option to include also category 2 SSNs for upgrade to 
4X designed for suspicious nodules might be useful in the future. Integration of 
shortterm follow-up to confirm persistence would prevent unnecessary invasive 
workup in 4B SSNs.
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3.1  Introduction
Pulmonary subsolid nodules (SSNs) are distinctive from solid nodules with 
respect to CT morphology and underlying pathology29. Among the group of SSNs, 
nonsolid (pure ground-glass) nodules are differentiated from part-solid nodules 
dependent on the presence of a solid component. In adenocarcinomas, the size of 
the solid component correlates with the presence of an invasive component on 
pathology, which has therapeutic and prognostic implications20,60. Nonsolid 
nodules are commonly associated with having a more indolent behavior compared 
to part-solid nodules in terms of doubling time and malignancy rate61–64. It is thus 
not surprising that management recommendations make a distinction between 
part-solid and nonsolid nodules17,29,30. Similarly, as solid nodules, SSNs do not 
always present as malignancies. SSNs are frequently caused by benign disease, 
e.g. infection, focal fibrosis, and organizing pneumonia8,26,40,41. Some guidelines 
therefore, recommend a 3-month follow-up CT to check lesion persistence for 
nonsolid nodules larger than 5 mm and part-solid nodules of all sizes29,65.
 The Lung Imaging Reporting and Data System (Lung-RADS) was published in 
2014 by the American College of Radiology (ACR) to standardize interpretation of 
screen-detected nodules and harmonize nodule management30. It consists of 
numerous categories depending on nodule type and diameter thresholds. Nodule 
management is adapted to the relative risk of the nodule to represent or develop 
into a malignancy. A summary of the Lung-RADS categories can be found in Table 3.1.
Table 3.1   Summary of Lung-RADS category 1 to 4X.
Category  
Descriptor
Category Malignancy
probability
Management recommendation
Negative 1 < 1% Continue annual screening  
with LDCT in 12 months
Benign appearance
or behaviour
2 < 1% Continue annual screening  
with LDCT in 12 months
Probably benign 3 1-2% 6-month LDCT
Suspicious 4A 5-15% 3-month LDCT; PET/CT may  
be used when there is a ≥ 8 mm 
solid component
4B/4X > 15% Chest CT with/without contrast, 
PET/CT and/or tissue sampling 
depending on the probability of 
malignancy and comorbidities. 
PET-CT may be used when there  
is a ≥ 8 mm solid component
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Nonsolid nodules are in Lung-RADS category 2 if the diameter is <20 mm. Nodules 
of that category are considered to have a “benign appearance or behavior” with 
a malignancy probability of < 1%30. Though known for their indolent behavior, 
studies have shown that nonsolid nodules may actually represent invasive 
 adenocarcinomas, especially when the lesion is larger than 10 mm35,36. This makes 
Lung-RADS category 2 susceptible to underestimation of the malignancy risk. 
At the other end of the risk spectrum are category 4B nodules, which represent 
the highest risk group with a malignancy probability score > 15%. They are 
characterized by a solid core of ≥8 mm and management recommendations for 
these lesions include a clinical chest CT, PET/CT, or a biopsy. Opposed to other 
guidelines29,65, Lung-RADS does not recommend a general 3-month low-dose 
follow-up for part-solid nodules to confirm persistence. Only category 3 part-solid 
nodules are recommended to have a 3-month follow-up. This makes category 4B 
lesions susceptible to overestimation of the malignancy risk because of the 
morphological overlap with transient infectious nodules that might receive 
unnecessary invasive diagnostics. Given the considerable management conse- 
quences, we were interested to investigate whether these two Lung-RADS categories 
reflect the proper malignancy risk and consequently appropriate management 
recommendations for SSNs.
 For these reasons, we applied Lung-RADS categories 2 and 4B to SSNs of the 
largest publicly available database of the National Lung Screening Trial (NLST). 
The purpose was to quantify the actual malignancy rates on a nodule base and 
compare these to the malignancy probabilities given by Lung-RADS.
3.2  Materials and methods
Study group and nodule annotations
Chest CT scans from the NLST were used in this study10. All chest CT scans with at 
least one SSN annotated by the NLST were analyzed, resulting in 3185 participants. 
The NLST was approved by the institutional board at each participating medical 
institution and participants provided written informed consent before 
randomization10. CT data, demographics, and information on nodule classification, 
location, and histology were made available from the NLST after approval of our 
project proposal.
 We selected the type of the SSN according to the NLST database. Longitudinal 
information about each SSN was needed, as well as which nodule resulted in lung 
cancer. However, the NLST did not use unique lesion identifications for nodules 
along the timeline, impeding determination of lesion persistence. Likewise, no 
information about solid core size was available in the NLST database. Thus, all 
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eligible lesions were reannotated by two medical students and a researcher with 
in-house software that uses unique lesion identifications for each nodule (CIRRUS 
Lung Screening, Diagnostic Image Analysis Group, Nijmegen, the Netherlands). 
Lobe location, size, nodule type, and section numbers stored in the NLST database 
were used to annotate and characterize each positive nodule (≥4 mm). Nodule 
classification as nonsolid or part-solid was adopted from the NLST database. 
Lesion annotation was done on baseline and follow-up CT scans. Lung-RADS 
categorization was done for nodules on baseline scans and only this data was 
subsequently analyzed. Information of follow-up scans was used to determine 
persistence and growth of SSNs to identify malignancies and infectious lesions.
Identification of malignancies on nodule base
NLST provides information on cancer diagnoses on participant level, but no data 
are available on which nodular lesion indeed represented the actual malignancy. 
Therefore, an experienced radiologist (ETS) identified those nodules that were 
most likely to be the malignancies. The procedure was aided by the anatomic 
information from the NLST pathology database. Since only the pulmonary lobe 
where the malignancy had been located and the year of diagnosis were provided 
by the NLST database, a scale from 0 to 4 was designed to code the likelihood of 
correct malignancy identification:
0 = No lesion visible in the tumour lobe at baseline.
1 = Lesion highly unlikely to represent cancer.
2 = No decision possible.
(Lesion located in the tumour-bearing lobe that could potentially develop into a 
malignancy over time, but diagnosis was made >1 year apart of the last available 
screening CT and available imaging did not reveal unequivocal signs of 
malignancy.)
3 = Lesion highly likely to represent cancer.
(Lesion located in the tumour-bearing lobe and imaging signs very suggestive 
for malignancy; however, diagnosis of malignancy was made > 1 year apart of 
the last available screening CT.)
4 = Cancer.
(Lesion located in the tumour-bearing lobe on a screening CT obtained in the year 
of tumour diagnosis and imaging signs very suggestive for malignancy).
Imaging signs suggestive for malignancy included spiculation of the solid 
component and/or evident growth on follow-up.
 Only lesions with scores 3 and 4 were included in the data analysis. All SSNs 
not indicated as being diagnosed as malignancies within the median 6.5 years of 
follow-up according to the NLST database were considered benign.
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Statistics
Malignancy rates, defined as number of malignancies divided by the total number 
of lesions in this category multiplied by 100, were calculated for both categories 2 
and 4B. Impact of variable size thresholds were calculated for nonsolid nodules in 
category 2. Percentages of transient and persistent lesions were calculated for 
both Lung-RADS categories.
3.3  Results
Study population
The NLST database lists in total 1897 Lung-RADS 2 SSNs. This set consists of 1742 
nonsolid nodules <20 mm and 155 part-solid nodules <6 mm. Of these nodules 
described in the NLST database, 94.4% (1644/1742) of the nonsolid and 94.2% 
(146/155) of the part-solid nodules could be securely located on the CT images, and 
thus 1790 Lung-RADS 2 SSNs were eligible for inclusion in this study. Reasons for 
lack of identification were incomplete DICOM data (N=41) or the fact that a lesion 
could not be found on the scan (N=66).
 Likewise, the NLST database lists 348 part-solid nodules ≥ 6 mm. Of these 
partsolid nodules ≥6 mm, 331/348 (95.1%) could be located on the scans. Among 
this group, 120 lesions had a solid core ≥ 8 mm, corresponding to Lung-RADS 4B. 
Reasons for lack of identification were incomplete DICOM data (N=7) or the lesion 
could not be found on the scan (N=10).
 Ten nodules (N=7 in Lung-RADS 2, N=3 in Lung-RADS 4B) had to be excluded 
in participants with score 0, 1, or 2 assigned during the malignancy identification 
process. Thus, the final study group included in the statistical analysis consisted 
of 1783 Lung-RADS 2 and 117 Lung-RADS 4B nodules.
Malignant nodules in Lung-RADS category 2
Forty-four of the Lung-RADS 2 lesions (2.5%; 44/1783) were found to be malignant 
(Table 3.2). The malignant lesions had an average diameter of 9.9 mm. The vast 
majority were nonsolid at baseline (N=42), the remaining two were part-solid. 
At baseline 20 lesions were <10 mm in diameter, 20 between 10 and 15 mm, and 
4 between 15 and 20 mm. Eight lesions were resected within 1 year of baseline, 
13 in year 1 after baseline, 11 in year 2 after baseline, and 12 in year 3 after baseline 
or later. Figure 3.1 shows examples of malignant category 2 lesions. Of the benign 
Lung- RADS 2 lesions, 30.1% (523/1740) were found to be transient. Thirty-four were 
part-solid and 489 were nonsolid. Of the transient nonsolid nodules at baseline 
391 were < 10mm in diameter, 83 between 10 and 15 mm, 15 between 15 and 20 mm.
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Impact of varying diameter thresholds on management of 
Lung-RADS 2 nonsolid lesions
Lowering the threshold from 20 to 15 mm, would have upgraded four of the 42 
nonsolid malignancies to a higher Lung-RADS category -and thus earlier follow-up 
(6 months)- at the expense of earlier follow-up scans for 49 benign nonsolid nodules. 
Accordingly, lowering the threshold from 20 to 10 mm, would have correctly 
upgraded 24 malignant nodules to an earlier follow-up but at the expense of 
earlier follow-up scans for 262 benign nonsolid nodules.
Benign Nodules in Lung-RADS category 4B
In this subset of nodules, 28/117 (23.9%) lesions were found to be malignant (Table 3.3). 
The remaining 89/117 (76.1%) lesions were found to be benign. Malignant 4B lesions 
had an average diameter of 18.0 mm. Eighteen lesions were resected within one 
year of baseline, six in year 1 after baseline, one in year 2 after baseline, and three 
in years 3 after baseline or later. Twenty-seven out of the 89 (30.3%) benign lesions 
were transient and were no longer present on the follow-up screening CT scan. 
Table 3.2   Malignancy rate of Lung-RADS category 2 subsolid nodules.
Lung-RADS category 2
(N = 1783*)
Malignant 44 (2.5%)
Nonsolid 42
Part-solid 2
Benign 1739 (97.6%)
No follow-up scan 129 (7.4%)
Nonsolid 122
Part-solid 7
Transient 523 (30.1%)
Nonsolid 489
Part-solid 34
Persistent 1087 (62.5%)
Nonsolid 984
Part-solid 103
Within the category 2 group of benign lesions both transient and persistent subsolid nodules can be 
found and are listed per nodule type. Persistence could not be determined in lesions with no follow-up 
scan available.
* excluding nodules with malignancy probability scores 0, 1, and 2 (N = 7 lesions)
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Six of the benign 89 nodules had no follow-up scan to confirm or exclude persistence. 
Figure 3.2 shows examples of transient and persistent category 4B lesions.
Figure 3.1  Examples of malignant Lung-RADS category 2 subsolid nodules 
between 10-15 mm.
a b c
Table 3.3   Malignancy rate of Lung-RADS category 4B subsolid nodules.
Category Descriptor Lung-RADS category 4B
(N = 117*)
Malignant 28 (23.9%)
Benign 89 (76.1%)
No follow-up scan 6 (6.7%)
Transient 27 (30.3%)
Persistent 56 (62.9%)
Within the category 4B group of benign lesions both transient and persistent subsolid nodules can be 
found. Persistence could not be determined in the lesions with no follow-up scan available.
* excluding nodules with malignancy probability scores 0, 1, and 2 (N = 3 lesions)
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3.4  Discussion
In 2014, the ACR published Lung-RADS for screen-detected pulmonary nodules. 
Similarly to other management recommendations, it differentiates nodule types 
and uses nodule diameter and growth as major input parameters29,30,48,65. Nodule 
management is adapted to estimated malignancy probability with category 2 
corresponding to the finding of a nodule with benign appearance and very 
low-risk of being a malignancy, and category 4B corresponding to the finding of a 
suspicious nodule with a high malignancy risk, requiring more intense diagnostic 
workup including biopsy or resection. In Lung-RADS, thresholds for nodule 
diameters and corresponding risk estimates had been determined by a consensus 
panel of experts and were based on publications of data on a summary-level of 
various screening trials including NLST, ELCAP, and NELSON66. Recently, Pinsky et 
al.66 published a retrospective analysis of the Lung-RADS performance in the 
NLST. Lung-RADS scores 1 and 2 were defined as negative and scores 3 to 4B as 
positive screening results. Performance was analyzed on participant level with 
respect to the presence of diagnosed malignancy. However, no individual nodules 
were tracked and no differentiation was made between part-solid nodules with 
various sizes of solid components (categories 3-4A-4B), since this information is 
not automatically available by the NLST-database. The fact that a subset of 
nonsolid nodules <20 mm in diameter is malignant was well discussed, but no 
further information on distribution of diameter with respect to histology was 
provided. We, therefore, focused our analysis on the two Lung-RADS categories 2 
and 4B, the first with respect to the presence of malignancies despite of low risk 
categorization, the latter because of its potential overcall of transient infectious 
lesions as high-risk nodules triggering substantial management consequences.
Figure 3.2  Examples of benign Lung-RADs 4B subsolid nodules, (a, b) persistent 
(c) transient.
a b c
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In our study, we found a malignancy rate of 2.5% in Lung-RADS 2 subsolid lesions 
and 23.9% for Lung-RADS 4B subsolid lesions. Malignancy-rates published by 
Lung-RADS that include all nodule types are <1% for Lung-RADS 2 and > 15% for 
Lung-RADS 4B.
 Lung-RADS chose for a relatively large cut-off of 20 mm for nonsolid nodules 
in the lowest risk category. Both the Fleischner Society and, if there is no previous 
imaging, also the British Thoracic Society, recommend an initial 3-month 
follow-up for nonsolid lesions ≥ 5 mm to assess persistence. The NCCN further 
differentiates between nodules <5 mm, 5- 10 mm, and larger and propose a 
generally closer followup for nonsolid nodules: ≤ 5 mm yearly LDCT, and for lesions 
>5-10 mm an LDCT in 6 months, and for lesions > 10 mm an LDCT in 3-6 months. 
Uniformly, all guidelines recommend more invasive diagnostics in subsolid 
nodules with new or growing (solid) components29,65,67. Pinsky et al.66 reported in 
their analysis of NLST data that Lung-RADS underestimates the likelihood of lung 
cancer in subjects with nonsolid lesions <20 mm or nodules < 6 mm.  In line with 
the findings reported by Pinsky     et al.66 our analysis of NLST nodules also showed 
a slight underestimation of the Lung-RADS 2 probability score in subsolid nodules 
(2.5% versus <1%).
 A recent publication by I-ELCAP reported that nonsolid nodules can be safely 
monitored with a 1-year follow-up scan59. Similarly, Scholten et al.57 found that 
long-term follow-up appears to be safe to check for changes in SSNs. There are, 
however, studies that have reported a non-negligible percentage of nonsolid 
lesions representing invasive carcinomas35,36. Hence, it is not yet clarified whether 
indeed all nonsolid nodules represent indolent malignancies or whether other 
texture features such as border characteristics or spatial attenuation characteristics 
beyond diameter or lack of solid component need to be considered to correctly 
assess malignancy risk68,69. Part of this controversy is most likely related to the 
variability of differentiating nonsolid from part-solid nodules37,47. A general 
lowering of the threshold to 15 or 10 mm seems not advisable given the 
disadvantage of inducing large numbers of false-positive follow-ups and the fact 
that I-ELCAP could not observe a stage shift/deterioration of patient outcome 
applying a 1-year follow-up strategy59. Interestingly 18% (8/44) of category 2 
malignancies were resected within 1 year of the screening CT, another 55% (24/44) 
within the following 2 screening years, supporting the idea that although 
classified as category 2 they displayed some morphological features that made 
them more suspicious. In addition to the size and nodule-type based categories 
Lung-RADS includes an additional category 4X triggering more intense diagnostic 
workup. This category is meant for categories 3, 4A, and 4B nodules that based on 
visual assessment of the radiologist demonstrate suspicious malignant imaging 
features justifying an upgrade to a more intense workup. Currently, category 2 
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lesions are not included in such a procedure. Therefore, instead of lowering 
diameter thresholds, it could be an option to also allow for a subset of category 2 
lesions an upgrade to category 4X, when radiologists find suspicious malignant 
imaging features. In that context it is noteworthy that according to Pinsky et al.66 
proportion of stage 1 cancers and 5-year lung cancer-specific survival were not 
found to be significantly different between malignancies in Lung-RADS category 
2 and malignancies in Lung-RADS categories 3, 4A, or 4B subjects, indicating that 
category 2 malignancies cannot all be considered as indolent66. Their results are 
thus at least partially controversial to the findings published by Yankelevitz et 
al.59. It has to be noted that we do not know how many of the Lung-RADS 2 subsolid 
lesions in our study group represented adenocarcinoma in situ (AIS) minimally 
invasive adenocarcinoma (MIA) or indeed invasive adenocarcinomas. AIS and 
MIA have a (near) 100% disease-free survival after resection and usually grow 
slowly70. Several studies have investigated which morphological features would 
allow for differentiating pre-invasive from invasive nonsolid lesions35,71. More 
research would be beneficial to reveal more insight in predictive morphological 
features of pre-invasive and invasive nonsolid nodules.
 Quantification of the potential overestimation of category 4B SSNs was the 
other purpose of our study. This phenomenon actually has a larger impact on 
patient management, since category 4B results in a more intense and potentially 
invasive workup including a “clinical chest CT, PET-CT, and/or tissue sampling 
depending on the probability of malignancy, comorbidities, and the radiologist’s 
final decision”30.
 Lung-RADS published an overall malignancy rate for all nodule types of > 15% 
for category 4B, which is in line with the malignancy rate of 23.9% we found in 
our analysis for SSNs. This indicates that from a statistical point-of-view there is 
no overestimation. However, more importantly, one-third (30.3%) of the benign 
4B SSNs were transient as confirmed by follow-up. Although we conclude that the 
statistical malignancy risk of Lung-RADS 4B SSNs is in agreement with the 
Lung-RADS guidelines, our results represent a strong argument to include a 
short-term follow-up after three months to confirm persistency before considering 
more invasive management strategies, as also has been suggested by other 
guidelines. The NCCN suggests to perform a LDCT in 3 months to check for growth 
when there is low suspicion of lung cancer in their highest risk group for part-solid 
nodules (> 8 mm lesion size). As for nonsolid nodules, the BTS recommends a 
3-month CT repeat in cases when there is no previous imaging to assess persistence, 
growth, or change in morphology for part-solid nodules as well. Similarly the 
Fleischner Guidelines, designed for incidental nodule findings, recommend 
always to do a short-term at 3 months to confirm persistence in all part-solid 
nodules29,65,67.
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In both categories, we found that about one-third of the lesions were transient. 
This is an important finding because it eliminates any need for further follow-ups. 
Previous studies report a wide range of numbers for the rate of transient SSNs 
(ranging between 12-70%)26–28,59,72. Lee et al.28 found a rather high rate of 70% of 
126 transient part-solid lesions seen in an Asian population. On the other hand, 
Yankelevitz et al.59 who analyzed screen-detected nonsolid nodules in a population 
comparable to the NLST, reported results more similar to our findings. Their study 
found that 26% (628/2392) of the nonsolid nodules seen at baseline screening 
subsequently resolved or decreased. The Multicentric Italian Lung Detection trial 
found similar results with 31% (15/48) of nonsolid nodules to be transient but a 
lower percentage of 12% (3/26) for part-solid nodules with a solid core < 5 mm72. 
Although our finding generally matches previous literature, rate of persistence in 
SSNs appears to be influenced by type and study group inclusion.
 Our study has some limitations. First, the most important limitation is the 
fact that SSNs not diagnosed as malignancies within a median period of 6.5 years 
were considered benign though no histological proof is available. However, this 
assumption seems to be acceptable based on current data knowledge and mirrored 
by the fact that current guidelines of the Fleischner Society recommend a 
maximum followup of SSNs of 5 years29. Second, a small subset of SSNs could not 
be localized as described in the methods section and were excluded. However, 
this concerned only a small percentage of nodules and therefore it seems unlikely 
to have substantially influenced results. The NLST does not provide any information 
which nodule actually represented the resected malignancy. The standard of 
which nodule was considered malignant was determined by an experienced 
radiologist having anatomic information and follow-up scans available. To exclude 
any indeterminate or doubtful lesions a scoring system was defined and only 
lesions with high confidence scores were included in the final analysis. Third, 
pathologic subtypes were not available in the NLST database at the time of analysis. 
Thus, further differentiation between AIS, MIA and invasive adenocarcinomas 
was not possible. Last, we used the nodule type classification of the NLST-database, 
which is based on the assessment of the local screening radiologist. Given the 
observer variability for the assessment of presence and size of the solid core, it is 
likely that a subset of SSNs might have been classified differently by other 
observers37,47. Taken together, the limitations might have slightly influenced the 
percentages described, but are considered unlikely to have any impact on our 
conclusions.
 In conclusion, malignancy probabilities for Lung-RADS 2 and 4B generally 
match the malignancy risks in SSNs. The slight statistical underestimation of 
nonsolid nodules appears to be clinically less relevant given the generally indolent 
character of these lesions and the fact that the management difference only refers 
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to the time interval of low-dose follow-up CT scans. An option to include also 
category 2 SSNs for possible upgrade to category 4X designed for more suspicious 
nodules might be considered in the future; however, more research is needed to 
define which imaging features qualify for such a procedure. Our finding that 
one-third of the benign 4B SSNs were transient and thus falsely categorized as 
relatively high risk nodules is of significant clinical importance. Integration of a 
short-term low-dose follow-up to differentiate persistent from transient lesions 
would avoid unnecessary invasive workup in Lung-RADS category 4B SSNs, and 
should, therefore, be considered in future upgrades of Lung-RADS.
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Abstract
Purpose: To assess the added value of including one-year growth on the performance 
of a risk calculator for the prediction of lung cancer in subsolid nodules (SSNs).
Methods: Subsolid nodules from the National Lung Screening Trial (NLST) were 
localized in baseline and follow-up CT scans. Malignancies were identified on CT 
using NLST-information. A nodule risk calculator (Brock model) was applied using 
morphologic nodule features and patient characteristics. Logistic regression was 
used to add one-year growth (in nodule diameter) to the calculator. Areas under 
the curve (AUCs) were determined.
Results: Applying the calculator to baseline SSNs (2187 nodules) yielded a high 
AUC of 0.893 (95% CI 0.871-0.915) for predicting lung cancer. Of the selected SSNs, 
1236 nodules (57%) were persistent after one year. Applying the calculator solely 
to persistent nodules yielded an AUC of only 0.872 (95% CI 0.843-0.901). Baseline 
nodule mass or nodule volume either individually or together did not further 
increase the performance of the risk calculator with AUCs ranging from 0.893 - 
0.898). Significantly improved AUC was achieved with one year growth information 
determined by semi-automatically measured effective diameter (AUC = 0.915, 
95% CI 0.891-0.939).
Conclusion: Lung cancer risk estimation in persistent SSNs over a follow-up of 
6.5 years can be significantly improved by adding short-term growth after one year 
to a risk calculator, allowing for a more personalized follow-up management, 
and reducing costs and risks of long-term follow-up.
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4.1  Introduction
In recent years, much research has been conducted on the natural history, 
 characteristics and behavior of subsolid nodules (SSNs). From the current 
literature, we now know that SSNs possess different biological characteristics 
compared to the more frequently seen solid nodules. SSNs have a relatively higher 
malignancy risk than solid nodules but usually grow more slowly6,24,26,39,59,62,73. 
Presence and size of a solid core have been shown to correlate with the pathological 
finding of invasive carcinomas20,21. However, a substantial proportion of SSNs are 
of benign entity, e.g. infection, hemorrhage, or focal fibrosis19. Numerous studies 
have shown that it seems safe to monitor SSNs by annual computed tomography 
(CT) scans over several years; biopsies are only encouraged if there is a substantial 
solid core29,57,59. Both the British Thoracic Society (BTS) guidelines, aimed at both 
screen-detected and clinical nodules, and the Fleischner guidelines, formulated for 
incidentally found nodules, recommend a short-term follow-up first to confirm 
persistence18,25. Interestingly such a short-term follow-up is not included in 
Lung-RADS, the guidelines for lung cancer screening with low-dose CT, published 
by the American College of Radiology (ACR)30.
 For screening participants in general, but especially for those with persistent 
SSNs, a risk prediction model would be helpful in prospectively assessing the 
probability of malignancy, allowing for an individual adjustment of follow-up 
intensity and length, matched to nodule risk. The Brock model is a malignancy 
calculator for pulmonary nodules and has been mathematically modeled to a 
screening database17. It takes nodule specific features, other imaging features, 
and patient demographic information into account but it is based on variables 
that can be assessed from a single CT scan, and does not consider any longitudinal 
information such as persistence or growth. Two external validation studies found 
good results for the Brock model on large screen-detected data. No separation was 
made for solid nodules and SSNs74,75. While for solid lesions evident growth within 
a few months and pathological findings on a PET scan reliably provide information 
about potential malignancy, current guidelines propose long-term follow-up for 
SSNs because of their slow growth.
 Given the fact that SSNs show much slower growth and frequently resolve on 
follow-up scan because of benign etiologies, we hypothesized that taking the 
information of one additional scan after one year into account would be beneficial 
in predicting the lung cancer risk more accurately.
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4.2  Materials and Methods
Dataset
For this study we used low-dose CT scans from the National Lung Screening Trial 
(NLST) trial. A comprehensive description of the study and CT-acquisition has 
been published previously10,43. Data from all participants with one or more SSNs 
in any CT screening round were requested, which amounted to 3194 participants. 
In 9 participants, CT scans had not been properly stored, thus we received scans 
from 3185 participants. Positive nodules were re-annotated using in-house software 
(CIRRUS Lung Screening, Nijmegen, the Netherlands) which provides semi-automatic 
volumetry and computer-aided detection. The NLST pathology- database provides 
information about anatomic lobe location, size and date of diagnosis but no specific 
nodule coordinates. An experienced radiologist therefore identified the malignant 
lesions following the information as provided by the NLST database, using a 
probability score on a scale from 0 to 4 (Table 4.1).
Table 4.1   Malignancies were scored using a probability score on a scale from 0 to 4.
Probability 
score
Definition
0 No lesion visible in the tumor lobe at baseline.
1 Lesion highly unlikely to represent cancer.
2 No decision possible. Lesion located in the tumor-bearing lobe that  
could potentially develop into a malignancy over time,  
but the diagnosis was made ≥ 1 year apart from the last available  
screening CT and available imaging did not reveal unequivocal  
signs of malignancy.
3 Lesion highly likely to represent cancer. Lesion located in the tumor 
bearing lobe and imaging signs highly suggestive of malignancy,  
however, diagnosis of malignancy was made > 1 year apart from
the last available screening.
4 Lesion compatible with cancer. Lesion located in the tumor-bearing  
lobe on a screening CT obtained in the year of tumor diagnosis
and imaging signs highly suggestive of malignancy*..
* Imaging signs used for identification of malignancy included nodule size, evident growth on 
follow-up and morphological features generally accepted as being suggestive for malignancy such 
as spiculation or perifocal parenchymal distortion. Only lesions with confidence scores 3 and 4 were 
included in the data analysis.
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Extended Brock model
Variables of the Brock model included age, sex, family history of lung cancer, 
emphysema and nodule characteristics (size, count, nodule type and lobe location). 
First, we tested whether adapting baseline features would improve the performance 
of the risk calculator. Variables tested included nodule volume, mass and continuous 
emphysema scores more accurately quantifying the extent of disease76, instead 
of a dichotomous variable for emphysema presence/absence. Second, we built an 
extended model of Brock to assess the added value of one-year growth in predicting 
lung cancer risk in SSNs. Growth was defined as the difference in effective diameter 
in millimeters. The effective diameter refers to the diameter computed from a 
sphere which has the same volume as the measured nodule volume.
Statistical analysis
Descriptive statistics were performed using the Fisher’s exact test (categorical 
data) and using the T-test (continuous data). First, the Brock model with original 
coefficients was validated on the baseline data for all SSNs and separately on the 
persistent SSNs (one-year follow-up). Second, multivariable logistic regression 
was applied to both datasets, thus creating new coefficients. Third, emphysema 
scores and nodule mass/volume were added to the baseline dataset. In the persistent 
dataset, we added growth information to the Brock model. To assess the impact of 
growth alone we computed the ROC curve using growth as a predictor of lung 
cancer risk estimation.
 Discriminative capacity of all prediction models was assessed using ROC 
analysis resulting in areas under the curve (AUCs) as a performance indicator. 
Differences between ROC curves were assessed using the method of Hanley et 
al.77. Statistical measures including sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV) and accuracy were calculated at an 
optimal risk threshold.
 Last, we performed an internal validation of the model including growth. 
A bootstrap resampling procedure using 500 iterations was used to assess the 
degree of over-optimism, i.e. the reduction between performance in the bootstrap 
sample and performance in the original sample78,79. The goodness of fit 
(calibration) was assessed using the Hosmer-Lemeshow test. Statistical analyses 
were performed using SPSS, version 20.0 (SPSS, Chicago, Ill, USA) and Matlab 2016a 
(Mathworks, Natick, MA, USA).
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4.3  Results
Nodule-based characteristics on baseline
Of the 2317 SSNs annotated by the NLST on baseline scans (year 0), 130 lesions 
could not be located (5.6%), due to missing DICOM (N = 52) or the fact that no 
lesions could be identified using the NLST information (N = 78). Additionally, 10 
lesions were excluded because a too low malignancy probability score of 0, 1 or 2 
had been attributed. Because of missing information of the variables (e.g. missing 
family history) 98 (4.2%) lesions had to be excluded, resulting in the final study 
group of 2079 lesions. Ninety-three SSNs visible on baseline were attributed a 
score 3 or 4 during the identification process of the malignancies and were thus 
included as malignancies in the analysis.
 The median size of the baseline nodules was 6.7 mm (IQR 5.1 mm - 9.4 mm) in 
benign nodules and 12.9 mm (IQR 10.5 mm - 17.3 mm) in malignant nodules  p < 0.001). 
Of the malignant nodules, 70% (65/93) were found in the upper lobe, compared 
to 54% (1069/1986) of the benign nodules (p < 0.003). Nodule type was nonsolid 
in 79% (1576/1986) of benign and in 47% (44/93) of malignant nodules (p < 0.001), 
Table 4.2.
Patient-based characteristics on baseline
The mean age was 62 (SD 5.2) year for benign and 63 (SD 5.0) for malignant cases 
(p = 0.016). A total of 937 (47%) were male in the benign cases and 41 (44%) in 
the malignant cases (p = 0.596). Emphysema was found in 748 benign (38%) and 
40 malignant cases (43%), p = 0.325, Table 4.2.
Validation of the Brock model on all baseline SSNs
The Brock model with its original coefficients achieved an AUC of 0.889 (95% CI 
0.867 - 0.911), for all baseline nodules.
Validation of the Brock model on all baseline SSNs with adapted 
coefficients and alternative input features
Applying the eight Brock variables with coefficients adapted to our baseline 
dataset, did not significantly increase the performance (AUC = 0.893, 95% CI 0.871 
- 0.915, p = 0.20). Adding alternative baseline features such as continuous 
emphysema scores, nodule mass or nodule volume either individually or together, 
did not further increase the performance of the risk calculator with AUCs ranging 
from 0.893 - 0.898.
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Validation of the Brock model on all persistent SSNs
Subsequent calculations considered only persistent SSNs. Of the 2079 baseline 
lesions, 1236 lesions were found to be persistent on the 1-year follow-up, of which 
50 were scored malignant (probability score 3 or 4). The Brock model with its 
original coefficients yielded an AUC of 0.867 (95% CI 0.836 - 0.897). Applying the 
Table 4.2   Distribution of study variables in subjects on the baseline scan,  
by lung cancer status.
Variable Benign  
n = 1986
Lung cancer  
n = 93
P-value  
Benign versus malignant
Age in years, mean (SD) 62 (SD 5.2) 63 (SD 5.0) p* = 0.016
Sex
Male 937 (47%) 41 (44%)
Female 1049 (53%) 52 (56%) p † = 0.596
Family history of lung cancer
No 1510 (76%) 62 (67%)
Yes 476 (24%) 31 (33%) p † = 0.048
Emphysema
No 1238 (62%) 53 (57%)
Yes 748 (38%) 40 (43%) p † = 0.325
Nodule type
Nonsolid 1576 (79%) 44 (47%)
Part-solid 410 (21%) 49 (53%) p † < 0.001
Nodule size (mm)
Mean (SD) 8.1 (4.8) 15.0 (7.4)
Median 6.7 12.9
IQR 5.1-9.4 10.5-17.3 p* < 0.001
Location
Lower lobe 917 (46%) 28 (30%)
Upper lobe 1069 (54%) 65 (70%) p † < 0.003
Nodule count
Mean (SD) 2.4 (1.5) 1.9 (1.1)
Median 2 1
IQR 1-3 1-3 p* = 0.001
IQR, inter-quartile range (from 25th to 75th percentile); † = p-value for Fisher’s exact test, * = p-value 
for T-test; SD, standard deviation. P-value < 0.05 was considered significant.
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Brock variables in a multivariable logistic regression, thus creating new coefficients, 
slightly but not significantly (p = 0.38) improved the performance with an AUC of 
0.872 (95% CI 0.843 - 0.901) on the one-year follow-up.
Extended Brock
Adding growth information to the Brock variables resulted in a significant 
performance improvement with an AUC of 0.915 (95% CI 0.891 - 0.939), p < 0.001. 
Examples of malignant SSNs with variable extent of growth can be found in 
Figure 4.1.
Growth as an individual variable
Growth, when used as an individual predictor for lung cancer, yielded inferior 
results with an AUC of 0.765 (95% CI 0.679 - 0.851).
Figure 4.1  (a,b) A malignant nonsolid lesion showing growth on follow-up 
(diameter 12.7 mm to 19.9 mm) (c,d) A malignant part-solid lesion showing 
growth on follow- up (diameter 12.8 mm to 17.1 mm) (e,f) A malignant non-solid 
lesion showing smaller amount of growth (diameter 16.3 mm to 18.4 mm)
a
d
b
e
c
f
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Parsimonious model only with significant variables: growth, 
nodule size and location
Nodule location (p = 0.005), nodule size (p < 0.001) and growth (p < 0.001) were 
significant predictors in the full growth model (Table 4.3).
 A parsimonious model was created using only these three variables and 
yielded an AUC of 0.909 (95% CI 0.882 - 0.936). Figure 4.2 shows the full and 
parsimonious growth models compared to the Brock model. Goodness-of-fit 
(calibration) was adequate (p > 0.05). The AUC of the parsimonious model was 
higher than the AUC with the Brock calculator variables only (p < 0.001). Table 4.4 
gives an overview of the AUCs on baseline and follow-up, and the subsequent 
p-value.
 Optimal risk thresholds were determined for both models (full and parsimonious) 
including growth (Table 4.5 and Table 4.6).
Figure 4.2  Both full and parsimonious growth models were significantly 
higher than the eight Brock variables on the one-year persistent set (p < 0.001 
and p = 0.003).
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At the optimal threshold, we found a high NPV, varying from 99.1% to 99.5% for 
the Brock model and both growth models. However, a substantially lower 
sensitivity was found with Brock (82.0%), compared to the parsimonious and full 
growth model (90.0 and 86.0%). At the threshold of zero false-negative nodules, 
meaning no malignant SSN would have been excluded from repeated follow-up 
after the first follow-up at one year, the full growth model showed the smallest 
number of false positives (373 (30.2%) with the full growth model versus 464 
(37.5%) with Brock and 453 (36.7%) with the parsimonious growth model). Thus at 
a zero false-negative rate, 91 (7.4%) lesions would be saved from long-term 
follow-up in the full growth model. Savings considerably increase to for example 
220 (17.8%) lesions at 10% false-negatives (5 out of 50 malignancies).
Growth model validation
Using bootstrapping we quantified the degree of over-optimism in the prediction 
models, which was applied to the ROC curve. This was small for both the 1-year 
follow-up full model and the parsimonious, 0.0162 (1.8%) and 0.0047 (0.52%), 
respectively.
Table 4.4   The areas under the curves (AUCs) when using the Brock variables 
on baseline and one-year follow-up dataset and the AUCs of  
the growth models are shown. The growth models are compared  
to the AUC of the adapted coefficients  in the one-year follow-up 
dataset. Brock model on baseline and one-year follow-up are 
compared between validation and adapted coefficients.
Model AUC CI P-value
Brock variables
Baseline (1986/93)
validation 0.889 0.867 - 0.911 0.20
adapted coefficients 0.893 0.871 - 0.915
One-year follow-up (1186/50)
validation 0.867 0.836 - 0.897 0.38
adapted coefficients 0.872 0.843 - 0.901
Growth models (1186/50)
Growth alone 0.765 0.679 - 0.851 0.02
Full growth model 0.915 0.891 - 0.939 < 0.001
Parsimonious growth model 0.909 0.882 - 0.936 0.002
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Table 4.5   Statistical measures for the models in the one-year persistent 
subsolid nodules. 
Model Risk  
threshold
Sensitivity  
(%)
Specificity  
(%)
PPV 
(%)
NPV 
(%)
Accuracy 
(%)
Brock (adapted coefficients)
optimal 5.5% 82.0 80.6 13.2 99.1 80.2
no false-negatives 2.2% 100 60.9 10.8 100 62.5
Full growth model
optimal 4.8% 86.0 82.2 17.0 99.3 82.4
no false-negatives 2.4% 100 68.5 11.8 100 69.8
Parsimonious growth model
optimal 4.3% 90.0 79.6 15.7 99.5 80.0
no false-negatives 1.9% 100 61.8 9.94 100 63.3
PPV = positive predictive value. NPV = negative predictive value.
Table 4.6   Nodule classification at optimal risk threshold. 
Model Risk  
threshold
True
positive 
nodules
False
positive 
nodules
True
negative 
nodules
False
negative 
nodules
Brock (adapted coefficients)
optimal
no false-negatives
5.5%
2.2%
41
50
230
464
956
722
9
0
Full growth model
optimal 4.8% 43 210 976 7
no false-negatives 2.4% 50 373 813 0
Parsimonious growth model
optimal 4.3% 45 242 944 5
no false-negatives 1.9% 50 453 733 0
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4.4  Discussion
SSNs frequently resolve on a follow-up scan because of benign etiologies. 
Furthermore, only a subset of the persistent SSNs eventually develops into 
malignancies, which can take several years57. On the other hand, especially those 
slowly growing adenocarcinomas presenting as SSNs have, if treated, a very good 
prognosis19,70. Therefore it is of special interest in a screening scenario to decide 
for invasive treatment of such SSNs at a time point where malignancy is proven 
but no stage shift has taken place. Thus, current guidelines recommend annual 
follow-up of several years until unequivocal growth or other findings suggestive 
of malignancy are seen. The most recent Fleischner guidelines propose a follow-up 
period of 5 years and the BTS guidelines a period of 4 years18,25. Results of the 
I-ELCAP study reported resection of nonsolid nodules after follow-up periods of up 
to 10 years59. Such long followup periods, however, lead to a considerable burden 
of dose, potential psychological stress and increase of financial expenses. 
Therefore we evaluated whether taking longitudinal information into account 
would lead to a more accurate prediction of lung cancer risk, which again could be 
used to further personalize management, and that way reducing costs and risks 
of follow-up.
 In our study group, 41% of the SSNs resolved after one year (843/2079) leading 
to a considerable reduction of SSNs requiring further follow-up. For the remaining 
persistent SSNs, we are the first to show that taking growth into account, 
significantly improves the malignancy risk estimation of the Brock model in SSNs 
(p < 0.001). Most importantly, information of only one-year follow-up resulted 
already in a significant improvement of lung cancer risk estimation.
 Furthermore, our results indicate that the growth model outperformed the 
Brock model, especially by achieving a higher sensitivity of 90%, at a similarly 
high level of specificity. For a large dataset, we could show that other factors such 
as gender, extent of emphysema, and family history do not play a significant role 
in the assessment of SSNs, underlying the notion that these slowly growing 
lesions might represent a subset of adenocarcinomas driven by other risk factors 
than the fast-growing solid adenocarcinomas. In addition, it has to be noted that 
information of growth alone only yielded insufficient performances.
 Validation of the Brock model was performed by the Danish Lung Cancer 
Screening Trial (DLCST), which reached high AUCs of 0.826-0.870, but did not 
reach 0.90. They hypothesized that the lower AUCs were due to the inclusion of 
many small nodules of 1-2 mm in the Brock development data while the DLCST 
included only nodules larger than 3 mm. A recent study by White et al.74 performed 
a similar validation of the Brock model using data of the NLST. The model gave 
good discriminative results between benign and malignant nodules with an AUC 
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of 0.963 (95% CI, 0.945-0.974). However, numerous malignancies had to be 
excluded because, as described in our methods, the malignancies were reported 
on a per-participant basis and not on a per-nodule basis. Therefore, only 
malignancies were included if the subject had shown a solitary nodule, which 
resulted in an exclusion of 33% of participants. We found lower discriminative 
values for our set of SSNs. Since we reannotated nodules in our study, we also 
included malignant nodules that were already visible on baseline, but were 
diagnosed as malignancies at a later point in time. Furthermore, we only included 
SSNs in our dataset. Zhao et al. validated the Brock model on SSNs as well80. They 
found AUCs of 0.890 for their set of SSNs. However, the database by Zhao et al. 
consisted of a much smaller number of SSNs (N = 52 baseline lesions) compared to 
our study. Our study shows a similar AUC of 0.889 (95% CI 0.867-0.911) for the 
baseline validation of SSNs and 0.867 (95% CI 0.836-0.897) for the persistent 
dataset. However, to reach AUCs above 0.90 we have shown that inclusion of 
growth information is needed. It is important to notice that this significant 
improvement was already seen after a one-year interval in which SSNs might 
have actually grown only very little.
 We calculated statistical measures for the models in the persistent nodules at 
the optimal risk threshold. Applying these thresholds, we found very high NPVs 
of more than 99% in all models which is essential to avoid unnecessary (invasive) 
management work-up especially if the majority of the nodules are benign. 
However, differences between the models were seen for the PPV. In that context 
we also found a higher sensitivity for the growth model compared to the Brock 
model (90 versus 82.0%) indicating that the growth model catches more true 
positive nodules (45 versus 41) and includes fewer false negatives (5 versus 9). At a 
zero false-negative lung cancer prediction, we found the number of false positive 
nodules to be considerably lower in the full growth model (N = 373), compared to 
the parsimonious (N = 453) and the Brock model (N = 464). Thus, including growth 
into the model helps to significantly reduce the need for long-term follow-up in 
patients with benign nodules.
Our study has limitations. First, we focused only on SSNs while the Brock model 
was developed and validated on all nodule types. We believe that in solid nodules 
growth also plays a large role and can be reliably detected given the higher 
volume doubling time and thus allows for appropriate management steps already 
after one or maximum two short-term follow-ups. In solid nodules, the inclusion 
of growth will therefore have less impact on long-term patient management. 
Second, the NLST database provides no information on malignant and benign 
character on a per nodule basis; therefore, we defined various confidence scores 
for annotating the malignancies and included only annotations of high confidence 
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(scores 3 and 4) in the analysis. We were also not able to differentiate between 
invasive and preinvasive subsolid malignancies since this information is not 
available from the NLST database. Third, we did not take into account the growth 
of the solid core in our model. It would have required a subcategorization of 
nonsolid versus part-solid nodules which is prone to substantial observer 
variability as described by several literature reports37,47. Finally, we validated our 
model only internally, therefore before advocating the model more broadly, an 
external validation on another dataset would be needed.
 In summary, our results show that including the information of a one-year 
followup improves the prediction of malignancy in subsolid nodules significantly. 
Growth, nodule diameter and lobe location were shown to be the most important 
parameters. Especially since SSNs are known for their indolent behavior, a 
mathematical model including growth could be applied to adapt follow-up length 
and interval to the individual nodule risk, that way improving screening 
efficiency.
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Abstract
The introduction of lung cancer screening programs will produce an unprecedented 
amount of chest CT scans in the near future, which radiologists will have to read 
in order to decide on a patient follow-up strategy. According to the current 
guidelines, the workup of screen-detected nodules strongly relies on nodule size 
and nodule type. In this paper, we present a deep learning system based on 
multi-stream multi-scale convolutional networks, which automatically classifies 
all nodule types relevant for nodule workup. The system processes raw CT data 
containing a nodule without the need for any additional information such as 
nodule segmentation or nodule size and learns a representation of 3D data by 
analyzing an arbitrary number of 2D views of a given nodule. The deep learning 
system was trained with data from the Italian MILD screening trial and validated 
on an independent set of data from the Danish DLCST screening trial. We analyze 
the advantage of processing nodules at multiple scales with a multi-stream 
convolutional network architecture, and we show that the proposed deep learning 
system achieves performance at classifying nodule type that surpasses the one of 
classical machine learning approaches and is within the inter-observer variability 
among four experienced human observers.
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5.1  Introduction
The American National Lung Screening Trial (NLST)10 demonstrated a lung cancer 
mortality reduction of 20% by screening of heavy smokers using low-dose 
Computed Tomography (CT), compared with screening using chest X-rays. 
Motivated by this positive result and subsequent recommendations of the U.S. 
Preventive Services Task Force81, lung cancer screening is now being implemented 
in the U.S., where high-risk subjects will receive a yearly low-dose CT scan with 
the aim of (1) checking for the presence of nodules detectable in chest CT and (2) 
following-up on nodules detected in previous screening sessions. As a consequence, 
an unprecedented amount of CT scans will be produced, which radiologists will 
have to read in order to check for the presence of nodules and decide on nodule 
workup. In this context, (semi-) automatic computer-aided diagnosis (CAD) 
systems82–85 for detection and analysis of pulmonary nodules can make the scan 
reading procedure efficient and cost effective.
 Once a nodule has been detected, the main question radiologists have to 
answer is: what to do next? In order to address this question, the Lung CT Reporting 
And Data System (Lung-RADS) has been recently proposed, with the aim of 
defining a clear procedure to decide on patient follow-up strategy based on nod-
ule-specific characteristics such as nodule type, size and growth. Lung-RADS 
guidelines also refer to the Brock model17, which estimates the malignancy 
probability of a pulmonary nodule detected in a baseline scan (i.e., during the first 
screening session) based on patient data and nodule characteristics. In both 
Lung-RADS guidelines and the Brock model, the key characteristic to define 
nodule follow-up management is nodule type.
 Pulmonary nodules can be categorized into four main categories, namely 
solid, non-solid, part-solid and calcified nodules (see Figure 5.1). Solid nodules are 
characterized by a homogeneous texture, a well-defined shape and an intensity 
above -450 Hounsfield Units (HU) on CT. Two sub-categories of nodules with the 
density of solid nodules can be considered, namely perifissural nodules86, i.e., 
lymph nodes (benign lesions) that are attached or close to a fissure, and spiculated 
nodules, which appear as solid lesions with characteristic spicules on the surface, 
often considered as an indicator of malignancy. Non-Solid nodules have an 
intensity on CT lower than solid nodules (in the range between -750 and -300 HU), 
also referred to as ground glass opacities. Part-Solid nodules contain both a 
non-solid and a solid part, the latter normally referred to as the solid core. 
Compared with solid nodules, non-solid and in particular part-solid nodules occur 
less frequent but have a higher frequency of being malignant lesions6. Finally, 
calcified nodules are characterized by a high intensity and a well-defined rounded 
shape on CT. Completely calcified nodules represent benign lesions.
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In Lung-RADS, the workup for pulmonary nodules is mainly defined by nodule 
type and nodule size. However, presence of imaging findings that increase the 
suspicion of lung cancer, such as spiculation, can modify the workup. In the Brock 
model, spiculation is a parameter that together with nodule type, nodule size and 
patient data contribute to the estimation of the malignancy probability of a 
nodule. Furthermore, completely calcified and perifissural nodules are given a 
malignancy probability equal to zero. In a scenario in which CAD systems are 
used to automate the lung cancer screening workflow from nodule detection to 
automatic report with decision on nodule workup, it is necessary to solve the 
problem of automatic classification of nodule type. In this context, the classes that 
have to be considered are: (i ) solid, (i i ) non-solid, (i i i ) part-solid, (i v) calcified, (v) 
perifissural and (vi ) spiculated nodules.
 Although the general characteristics of nodule types can be easily defined, 
recent studies47,87 have shown that there is a substantial interand intra-observer 
variability among radiologists at classifying nodule type. In this context, researchers 
Figure 5.1  Examples of triplets of patches for different nodule types in axial, 
coronal and sagittal views. Each triplet is depicted using three different patch 
sizes, namely 10 mm, 20 mm and 40 mm.
axial coronal sagittal
patch size = 10 mm
axial coronal sagittal axial coronal sagittal
patch size = 20 mm patch size = 40 mm
calcified
perifissural
solid
non-solid
part-solid
spiculated
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have addressed the problem of automatic classification of nodule type in CT scans 
by (1) designing a problem-specific descriptor of lung nodule and (2) training a 
classification model to automatically predict nodule type. In87, nodules were 
classified as solid, non-solid and part-solid. A nodule descriptor was designed 
based on information on volume, mass and intensity of the nodule, and a kNN 
classifier was applied, but the used features strongly rely on the result of a nodule 
segmentation algorithm, whose optimal settings also depend on nodule type. 
The authors propose to solve this problem by first running the algorithm multiple 
times using different segmentation settings in order to extract features and then 
classify nodule type. In practice, this strategy hampers the applicability of such a 
system to an optimized scan reading scenario. In88, the SIFT descriptor was used 
to classify nodules as juxta, well circumscribed, pleural-tail and vascularized, 
and a feature matching strategy was used for classification purposes. Despite the 
good performance reported, the considered categories are not relevant for nodule 
management according to current guidelines. A descriptor specifically tailored for 
lung nodule analysis was introduced in89, which was used to assess presence of 
spiculation in detected solid nodules90 and to classify nodules as perifissural91. 
Although this approach could be extended to other nodule types, it strongly relies 
on the estimation of nodule size in order to define the proper scale to analyze data.
 Scale is an important factor to consider in automatic nodule type classification. 
As an example, discriminating a pure solid nodule from a perifissural nodule 
involves the detection of the fissure, which on a 2D view of the nodule can be 
differentiated from a vessel only if a sufficiently large region surrounding the 
nodule is considered (see Figure 5.1). On the other hand, discriminating non-solid 
from part-solid nodules strongly relies on the presence of a solid core, which can 
consist of a tiny part of the lesion that can only be clearly detected on a small 
scale.
 In recent years, the advent of deep learning31,92 has emerged as a powerful 
alternative to designing ad-hoc descriptors for pattern recognition applications 
by using deep neural networks, which can learn a representation of data from 
the raw data itself. The most used incarnation of deep neural networks are 
convolutional networks31,93,94, a supervised learning algorithm particularly suited 
to solve problems of classification of natural images94–96, which has recently been 
applied to some applications in chest CT analysis85,91,97–99.
 In this paper, we address the problem of automatic nodule classification by 
introducing three main contributions. For the first time, we propose a single 
system that classifies all nodule types relevant for patient management in lung 
cancer screening according to the Lung-RADS assessment categories and the 
Brock malignancy probability model, namely solid, non-solid, part-solid, calcified, 
perifissural and spiculated nodules. Differently from what has been done in 
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previous work, we design a classification framework based on Convolutional 
Networks (ConvNets)92–94. In particular, we propose a multi-stream multi-scale 
architecture in which ConvNets simultaneously process multiple triplets of 2D 
views of a nodule at multiple scales and compute the probability for the nodule to 
belong to each one of the six considered nodule types. The proposed approach does 
not require nodule segmentation or the estimation of nodule size. Inspired by 
recent work85,91, we formulate the analysis of a nodule as a combination of 2D 
patches. Relying on the experimental results of Setio et al. Setio et al. 85 , which 
showed that performance increase by increasing the number of analyzed patches, 
we go beyond a limited number of patches by introducing a novel approach to 
extract an arbitrary number of 2D views from a nodule. We trained the deep 
learning system using data from 943 patients and 1,352 nodules from the 
Multicentric Italian Lung Detection (MILD) trial100 and we validated the trained 
system using independent data from 468 patients and 639 nodules from the 
Danish Lung Cancer Screening Trial (DLCST)101. Furthermore, in order to compare 
the performance of our deep learning architecture versus classical approaches of 
patch classification, we trained a linear support vector machines classifier to 
classify both features based on the raw intensity of nodules and features learned 
from raw data via an unsupervised learning approach. Finally, in order to compare 
the performance of our method versus human performance, we designed an 
observer study in which four observers, including experienced radiologists, 
classified a subset of 162 nodules extracted from the test set. We show that the 
proposed system achieves performance that surpasses classical patch 
classification approaches and is comparable with the inter-observer variability 
among human observers.
5.2  Materials and Methods
The input of the proposed framework is a chest CT scan and the position q = [x, y, 
z] of the nodule (e.g., its center of mass) to classify. The output of the system is the 
probability for the nodule to belong to each one of the six considered classes. The 
framework is based on convolutional networks (ConvNet), which process input 
samples via a “multi-stream multi-scale” architecture (see Fig. 5.2). We define an 
input sample as a triplets of 2D patches obtained by intersecting the 3D domain of 
the nodule with triplets of orthogonal planes, and crop triplets of patches at 
different resolutions. Therefore, an input sample to feed the deep learning system 
is given by three triplets of patches from the same nodule (see Fig. 5.2). Each step 
of the proposed framework is detailed in next sections.
Automatic classification of nodule types | 89
5
Fi
gu
re
 5.
2  
(a
) E
xa
m
pl
es
 of
 tr
ip
le
ts
 of
 n
od
ul
es
 ex
tr
ac
te
d 
by
 v
ar
yi
ng
 th
e p
ar
am
et
er
 N
 . (
b)
 E
xa
m
pl
es
 o
f p
yr
am
id
al
 tr
ip
le
ts
  
of
 p
at
ch
es
 u
se
d t
o f
ee
d t
he
 p
ro
po
se
d d
ee
p 
lea
rn
in
g s
ys
te
m
s. 
Th
e s
ys
te
m
 co
ns
ist
s o
f t
hr
ee
 g
ro
up
s o
f t
hr
ee
 st
re
am
s, 
on
e f
or
 ea
ch
 
co
ns
id
er
ed
 sc
al
e (
na
m
el
y 1
0 
m
m
, 2
0 
m
m
 an
d 4
0 
m
m
 fo
r p
at
ch
 si
ze
). C
on
vo
lu
tio
na
l la
ye
rs
, m
ax
po
ol
in
g l
ay
er
s, 
fu
lly
-c
on
ne
ct
ed
 
la
ye
rs
 an
d o
ne
 so
ft-
m
ax
 la
ye
r a
re
 th
e b
ui
ld
in
g b
lo
ck
s o
f t
he
 p
ro
po
se
d n
et
w
or
k. 
Th
e l
as
t f
ul
ly
-c
on
ne
ct
ed
 la
ye
r w
ith
 25
6 
ne
ur
on
s 
se
rv
es
 as
 a 
co
m
bi
ne
r o
f t
he
 th
re
e s
et
s o
f t
hr
ee
 st
re
am
s, 
an
d a
 6
-v
al
ue
 p
ro
ba
bi
lit
y v
ec
to
r i
s g
en
er
at
ed
 as
 ou
tp
ut
.
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
FC
-12
8
FC
-12
8
FC
-12
8
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
FC
-12
8
FC
-12
8
FC
-12
8
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
32@
5x5
poo
ling
2
64@
3x3
poo
ling
2
128
@3
x3
poo
ling
2
256
@3
x3
poo
ling
2
FC
-12
8
FC
-12
8
FC
-12
8
FC
-25
6
sof
tma
x-6
sca
le 1
0 m
m
sca
le 2
0 m
m
sca
le 4
0 m
m
con
volu
tion
al la
yer
 (n_
filte
rs@
filte
r_s
ize 
x fil
ter_
size
)
poo
ling
 lay
er (
poo
ling
win
dow
_siz
e)
fully
-co
nne
cte
d la
yer
 (FC
-n_
uni
ts)
sof
t-m
ax 
laye
r (s
oftm
ax-
n_u
nits
)
P
(a)
(b)
axia
l
cor
ona
l
sag
itta
l
q=
[x,y
,z]
d =
 10
mm
 (64
 px
)
d =
 20
mm
 (64
 px
)
d =
 40
mm
 (64
 px
)
64@
3x3
64@
3x3
64@
3x3
64@
3x3
64@
3x3
64@
3x3
64@
3x3
64@
3x3
64@
3x3
a
b
90 | Chapter 5
Generation of triplets of 2D patches
Let us define a triplet of orthogonal planes Tn = {Ψn, Ωh, Φn} passing through the 
point q and an angle θn = (n–1)π
 (n = 1, . . . , N ), which defines the rotation of each 
plane of Tn with respect to the axes x, y, z. In this way, T1 is the triplet of planes that 
define the default axial, coronal and sagittal views of a CT scan, and any other 
triplet Tn is obtained by sequentially rotating the triplet with respect to the x, 
the y and the z axis by an angle θn. Rotating all the planes by the same angle 
guarantees that orthogonal planes are always obtained. Examples of triplets for 
several values of N are depicted in Figure 5.2(a), where the axial, coronal and 
sagittal planes are represented in different colors.
 The intersection of a triplet of planes and a CT scan generates 2D views of the 
nodule of interest. From each intersection, we generate triplets of 2D patches by 
cropping a square area of size d centered on q. Increasing the value of N allows to 
increase the number of extracted patches per nodule, which also increases the 
coverage of the volume of a nodule in 3D. Furthermore, adapting the value of 
N per nodule type has the advantage of (1) balancing classes distribution in the 
presence of skewed distribution of classes by using a larger value of N for under-
represented classes, and (2) using it as a kind of data augmentation, in which 
many different views of the same object are extracted.
 The parameter d defines the scale at which patches are considered. Using 
multiple values of d allows to crop triplets of patches with information that range 
from local content to more global context of nodule appearance. In order to train 
the proposed deep learning system, we extracted triplets of patches at three 
different scales, namely d = 10, 20, 40 mm and fed three streams of the network 
with three triplets at the same time. This allows the network to focus both on the 
local appearance of a nodule (10 mm), where small structures like the solid core 
can be analyzed, and on more global context (40 mm), in which structures like the 
fissure can be recognized. Before feeding the network, each patch was rescaled to 
a fixed size of 64×64 pixels using bicubic interpolation and the pixel intensity 
IHU  [−1200, 400] HU was rescaled to Inor m  [0, 1] by applying the transformation 
Inor m = IHU +1200
 .
Deep learning network
Network design
The architecture of the used deep learning system is depicted in Figure 5.2(b). The 
system consists of nine streams of ConvNets, grouped into three sets of three 
streams. Each set of streams is fed with a triplet of orthogonal patches extracted 
at the same scale. Different sets of streams process triplets of orthogonal patches 
2N
1600
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with exactly the same orientation in the CT scan, but at different scales. Each 
stream of the set is fed with one patch from a triplet of orthogonal patches. The 2D 
input patch is then processed by a series of convolutional and pooling layers, with 
one last fully-connected layer. The size of each patch is 64×64 pixels, which covers 
a size of ≈ 40 mm at the used in-plane resolution of 0.67 mm/px.
 In order to define the optimal architecture for each stream, we followed the 
VGG- net approach proposed in102. We set a fixed size of convolutional kernels to 
33 px and used 32 filters in the initial layer. Similarly to102, we added pairs of 
convolutional and max-pooling layers, keeping a fixed filter size of 3×3 and 
doubling the number of filters in convolutional layers after each max-pooling, as 
long as the performance on the validation set were improving. We slightly 
deviated from the fixed procedure of102 by increasing the filter size in the first 
convolutional layer to 5 × 5 and by using 2 layers of 64 filters in cascade before the 
second max-pooling layer, since this configuration showed to perform slightly 
better than the standard one. The described architecture represents one of the 
three streams used in a set, which we define as multi-stream network. All the 
parameters of the network are shared across the three streams in the same 
multi-stream network. It is worth noting that a multi-stream network processes 
triplets of 2D patches extracted with the same resolution d .
 We used three scales with patch size of 10 mm, 20 mm and 40 mm, respectively, 
and for each scale we trained a multi-stream network. Each multi-stream network 
has the same architecture, but parameters are optimized independently at each 
scale. The multi-stream networks at different scales are finally merged in a final 
fullyconnected layer (see Figure 5.2(b)). The final soft-max layer has six neurons, 
which produce the probability for the six considered classes. We implemented the 
network using Theano103.
Training
We trained the proposed multi-stream multi-scale convolutional network with 
data from the MILD trial. For training purposes, we split the dataset into two 
parts, a training set containing 75% of the data, and a validation set, containing 
the remaining 25% of the data. We defined the two data sets without any overlap 
of patients or nodules across the sets and distributing all nodule types in the two 
sets based on the same proportion 75%-25%. The statistics of the two data sets are 
reported in Table 5.1.
 For training purposes, for each nodule, three triplets of patches were extracted. 
Each triplet was extracted at a given scale by setting the values d1 = 10 mm, d2 = 20 
mm and d3 = 40 mm for the streams 1,2, and 3 respectively. Since the distribution 
of nodule types were skewed, we adapted the number of angles N per nodule 
type. In order to set the proper value for N , we decided to initially extract 5,000 
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training samples per nodule class. Specific values for N for each class are reported 
in Table 5.1. Adapting the value of N per nodule type produced 30,000 training 
samples. We further augmented the size of the training data set by adding three 
shifted versions of each training sample. Data augmentation was therefore done 
by randomly shifting the position q of the center of mass of the nodule to qshi f t = 
[x + δx , y + δy , z + δz ], where (δx , δy , δz ) were drawn from a normal distribution 
with mean value µ= 0 and standard deviation σ =  1  , which ensures shifting 
within a sphere of radius 1 mm centered on q. Finally, each patch of the triplet and 
its shifted version were flipped along the vertical, the horizontal axis, and a 
combination of the two axes. As a result, 16 different views of each nodule sample 
were included in the training set, which resulted in approximately 500,000 
training samples.
 In order to train the ConvNet, we initialized the parameters according to the 
method in104 and trained using stochastic gradient descent, minimizing the 
categorical cross-entropy loss. During optimization, we set an initial learning rate 
η = 10–3 and decreased it by a factor 3 every 50 epochs. The parameters of the 
network were updated using the ADAM algorithm105. We set the batch size to 256 
and used dropout94 with a probability of 0.5 in the last fully-connected layer. 
Additionally, L2 normalization was used, with a weight decay parameter of 10–6. 
We empirically noticed that the training converges after ≈ 200 epochs.
Prediction
Given an input sample x, consisting of a set of triplets extracted at multiple scales, 
the trained architecture is able to predict a probability Pk (x) for each considered 
nodule type class k. Since one set of triplets is extracted for a given angle θ, the 
prediction also depends on the angle θ. Therefore, the input triplet for a given 
nodule can be written as a function of θ, namely xθ. In order to classify a given 
nodule, the prediction becomes a function of the parameter θ as well, which we 
can write as P (xθ). The final prediction is obtained as a combination of the N 
predictions obtained by varying the parameter θ.  The adopted combination 
strategy consisted in averaging the per-class probability, and finally assigning 
the nodule the label y = ar g maxk ( 1 Σ
 
N  Pk (xθ )). This prediction strategy was 
applied both during training to assess the performance of the network on the 
validation set, and during the final evaluation on the DLCST data set. For validation 
purpose, after each epoch, all nodules in the validation set were tested and 
performance was assessed. For this purpose, 30 samples per nodule were extracted 
(N = 30), meaning that patches at rotation st of 6º were taken. At each iteration, 
nodule type was predicted using the proposed combination of predictions, and 
quantitative performance parameters were computed. Since the distribution of 
nodule types in the validation set is skewed (see Table 5.1), we considered the 
3√3
N i =1 i
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F-measure per class instead of the commonly used accuracy, since the F-measure 
is less sensitive to skewed distributions. Based on this, during training we 
maximized the mean F-measure across classes. For the final evaluation on DLCST 
data, the same settings using N =30 was used, and the results for the three 
considered architectures reported in Table 5.2 and Table 5.3 were obtained.
Nodule classification using Support Vector Machines
In this section, we describe the details of the experiments based on classical 
machine learning approaches, where we used two different sets of features. 
The first set consists of features based on the intensity of pixels in 2D patches. 
The second set consists of features automatically learned from raw data in an 
unsupervised fashion, using the K-means algorithm.
Intensity features
The first set of features consists of the raw pixel intensity (HU values) extracted 
from 2D patches. Given a patch of size 64×64 px, we extracted a feature vector by 
vectorizing the values of pixel intensities in the patch. In this way, each patch had 
a 4,096-dimension feature vector. We built a training set by considering all the 
nodules used to train the methods based on deep learning, balancing samples 
across classes using the coefficients reported in Table 5.1. We used the training set 
to train a linear Support Vector Machines (SVM) classifier. Data were normalized 
prior to training to have zero mean and unit variance, and the one-vs-one strategy 
was used to deal with the multi-class problem. After training, we applied the classifier 
to the t e stALL dataset, which contains 634 nodules. As done for the evaluation of 
deep learning approaches, 30 patches per nodules were considered at test time, 
which were all classified using the trained SVM classifier. Finally, majority voting 
of the predicted labels was used to obtain the final prediction of nodule type.
Unsupervised features
The approach used to learn a representation of pulmonary nodules in an automatic 
unsupervised fashion is based on the work of Coates et al.106. The original method 
presented in106 was developed based on the CIFAR10 dataset, which contains RGB 
images of 32×32 px. Since the size of the patches used in this paper is 64×64 px, in 
order to apply the method in106 to our data we doubled the receptive field size, 
which we set to 12 px, and set the number of centroids to 1,600, which gave a 
feature space of 6,400 dimensions. We kept the rest of parameters of the algorithm 
at their default value. As done for the experiment using intensity features and 
linear SVM, at test time we classified 30 samples per nodule and considered the 
label given by the majority voting on the predicted labels as the final prediction of 
nodule type.
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5.3  Results
Training data
We trained the deep learning system using data from the Multicentric Italian 
Lung Detection (MILD) trial100. For this purpose, we considered all baseline CT 
scans from the MILD trial. The study was approved by the Institutional review 
board of Fondazione IRCCS Istituto Nazionale Tumori di Milano, and the written 
informed consent was waived for the retrospective examination of the analyzed 
data. For all patients, non contrast-enhanced low-dose CT scans were acquired 
using a 16-detector row CT system, with section collimation 16 × 0.75 mm. Images 
were reconstructed using a sharp kernel (Siemens B50 kernel, Siemens Medical 
Solutions) with a slice thickness of 1.0 mm. Nodules were detected and annotated 
based on the following procedure. All CT scans were first read by a workstation 
(CIRRUS Lung Screening, Diagnostic Image Analysis Group, Radboudumc, Nijmegen, 
Netherlands) with automatic nodule detection (CAD) tools integrated. Two medical 
students, trained by a radiology research in detecting pulmonary nodules, either 
accepted or rejected CAD marks and labeled nodules as one of the considered 
nodule types. Accepted nodules were segmented using the algorithm presented 
in107, which is implemented in CIRRUS Lung Screening. The students manually 
adjusted parameters to obtain the best possible nodule segmentation, which 
allowed to compute the equivalent diameter of the lesion. Nodules with label 
disagreement were reviewed by a thoracic radiologist (ES) with more than 
20 years of experience in reading chest CT scans. Nodules with label agreement 
were further reviewed by two radiology researchers (SvR, KC) independently. 
From the set of annotated nodules, we removed all cases with a diameter smaller 
than 4 mm, which is considered as an irrelevant finding in lung cancer screening10. 
The final set of data consisted of 1,805 nodules from 943 subjects (see Table 5.1), 
which were split into two non-overlapping sets: a training set (1,352 nodules), used 
to train the deep learning system and a validation set (453 nodules), used to 
monitor the performance of the system during training.
 In the development of the proposed deep learning system, we defined a 
nodule data sample as a set of triplets of patches (axial, coronal and sagittal view), 
where each triplet was used to feed three streams of convolutional network 
(details on data preprocessing, system design and training are detailed in the 
Methods section). For training purposes, several different samples were extracted 
from the same nodule by rotating triplets around the center of mass and by using 
techniques of data augmentation at patch level. In this way, ≈ 0.5M training 
samples were extracted and used to train the deep learning system. In our 
experiments, we investigated the performance of the system when data at 
different scales were considered. For this purpose, we extracted nodule data 
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with patches of size 10 mm, 20 mm and 40 mm, which represent 3 different scales. 
We built and trained three network architectures where one scale (40 mm), two 
scales (20 mm, 40 mm) and three scales (10 mm, 20 mm, 40 mm) were processed, 
and compared the performance of the three networks with both classical patch 
classification approaches based on machine learning and human performance.
Test data
The performance of the trained deep learning system was assessed on data from 
the Danish Lung Cancer Screening Trial (DLCST)101. In particular, we used the 
subset of data used in a study recently published by the DLCST research group75, 
where the authors also describe the procedure used to annotate nodule types. 
The DLCST was approved by the ethics committe of Copenhagen County and 
fully funded by the Danish Ministry of Interior and Health. Approval of data 
management in the trial was obtained from the Danish Data Protection Agency. 
The trial is registered with ClinicalTrials.gov (NCT00496977). All participants 
provided written informed consent. Non contrast-enhanced low-dose CT scans 
were acquired using a multi-slice CT system (16-row Philips Mx 8000, Philips 
Medical Systems) with section collimation 16 × 0.75 mm. Images were 
Table 5.1   Detailed number of nodules and samples in the training, validation 
and test sets. The MILD dataset is used for training and validation 
purposes, the DLCST dataset is used for testing purposes.  
In the test set, the number of nodules per class randomly selected  
to design the observer study is reported. The number of class-specific 
planes per nodule used to extract training data (N , see also  
Figure 5.2) is indicated for each nodule type. The number of used 
patients from MILD and DLCST are also indicated.
MILD (943 patients) DLCST (468 patients)
Training 
nodules
N Training 
samples
Validation 
nodules
Test nodules 
t e st ALL/ t e stOB S
Solid 694 8 88,832 232 382 / 27
Calcified 233 22 82,016 78 58 / 27
Part-solid 63 80 80,640 21 37 / 27
Non-solid 152 33 80,256 50 87 / 27
Perifissural 181 28 81,088 62 48 / 27
Spiculated 29 167 77,488 10 27 / 27
Total 1,352 – 490,320 453 639 / 162
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reconstructed using a sharp kernel (kernel D) with a slice thickness of 1.0 mm. 
From the initial data set, we removed nodules with a diameter smaller than 
4 mm, as done for data from the MILD trial, and discarded scans with incomplete 
or corrupted data (e.g., missing slices). Finally, we obtained a set t e stALL of 
639 nodules from 468 subjects (see Table 5.1), which we used for testing purposes.
Observer study
In order to compare the deep learning system with human performance, we 
selected a subset of nodules from the set t e stALL and asked three observers to label 
nodule type.  For this purpose, we built a dataset by including all spiculated 
nodules in t e stALL (27 nodules) and the same number of nodules randomly 
selected from the other classes. Therefore, a dataset t e stOBS of 162 nodules was 
built for the observer study. Two chest radiologists (ES, CSP) with more than 20 
years of experience reading chest CT and a radiology researcher (KC) were involved 
in the observer study. Readers independently labeled nodule types. Nodules were 
shown at locations indicated by annotations provided by the DLCST trial, and 
readers had the possibility to either label the nodule as belonging to one of the six 
considered categories, or label it as not a nodule. For evaluation purposes, we 
considered annotations made by the three observers involved in this study as 
well as annotations coming from the DLCST trial, which we considered as an 
additional observer. In the rest of the paper we will refer to annotations coming 
from these four different sources as observers O1, O2, O3 and O4 (where O4 indicates 
the DLCST annotations).
Evaluation
After training, all nodules in t e stALL were classified using the trained deep 
learning system. In order to compute the computer-observer agreement, we 
compared the results from the computer with the nodule type given by each 
observer independently in the t e stOBS set. Furthermore, we computed the 
inter-observer agreement by considering all possible pairs of observers Oi vs. Oj 
(i , j = 1, . . . , 4, i /= j ). In this case, since observers were given the possibility of 
labeling a given nodule as “not a nodule”, the additional class not a nodule is 
considered to assess the inter-observer variability. The results in terms of κ value are 
reported in Table 5.2, when all pairs of observers and the results from the three deep 
learning architectures working with different scales are considered. It can be 
noted that human observers have a moderate to substantial agreement, with κ 
between 0.59 and 0.75, and that the deep learning system achieves a variability 
in the same range of human observers, with a level of agreement that increases 
with the number of scales used for nodule classification. When the 3-scale 
architecture is considered, the κ value between the computer and each observer 
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under test is between 0.58 and 0.67 and in half of the cases, it is higher than the 
agreement between the observer under test and at least one of the other observers.
 We also evaluated the classification performance of the best performing 
network, namely the one working with 3 scales, in terms of accuracy and per-class 
F-measure and compared it with human performance (Table 5.3). It is worth 
noting that the average performance among human observers are comparable 
with the average performance between the computer and observers, with an 
average accuracy of 72.9% versus 69.6% respectively. A similar trend can be 
observed for all the other classification parameters.
 Furthermore, we used the t e stALL dataset to compare the performance of the 
proposed deep learning system with two classical approaches where a linear 
Support Vector Machines (SVM) classifier was trained in a supervised fashion 
using features extracted from 2D nodule patches. In the first approach, features 
based on the raw pixel intensity of 2D patches were used (intensity features). In 
the second approach, features were not engineered but learned from raw data via 
an unsupervised learning approach using the K-Means algorithm (unsupervised 
features), as proposed in106.
Details on the design of these two additional experiments are given in the 
Methods section. The proposed approach based on deep learning, together with 
these two approaches based on classical machine learning, covers a scenario 
where the problem of nodule classification is tackled by (1) manually defining 
features based on raw image data and use them to train a classifier, (2) learning 
Table 5.2   Cohen κ statistics with 95% confidence intervals for agreement 
between computer and observers. Oi indicates the i-th observer. 
Results for automatic classification using deep learning systems  
with different numbers of scales are reported.
Observers Computer
O1 O2 O3 O4 1 scale 2 scales 3 scales
O1 – 0.59  
(0.51–0.68)
0.65  
(0.57–0.74)
0.68  
(0.60–0.76)
0.63  
(0.54–0.72)
0.64  
(0.55–0.73)
0.65  
(0.57–0.74)
O2 0.59  
(0.51–0.68)
– 0.71  
(0.63–0.79)
0.66  
(0.58–0.75)
0.55  
(0.45–0.64)
0.54  
(0.45–0.64)
0.58  
(0.49–0.67)
O3 0.65  
(0.57–0.74)
0.71  
(0.63–0.79)
– 0.75  
(0.67–0.82)
0.56  
(0.47–0.65)
0.57  
(0.48–0.66)
0.61  
(0.52–0.70)
O4 0.68  
(0.60–0.76)
0.66  
(0.58–0.75)
0.75  
(0.67–0.82)
– 0.62  
(0.53–0.70)
0.64  
(0.55–0.73)
0.67  
(0.59–0.75)
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features from raw data in an unsupervised fashion and use them to train a 
classifier, (3) learning a hierarchical representation of nodules from raw data, 
using convolutional networks trained end-to-end. The results of the comparison 
are reported in Table 5.4, where the gradual improvement from using intensity- 
based features and SVM to a 3-scale approach based on deep learning can be 
observed both in terms of accuracy and F-measure.
 In Figure 5.3, examples of nodule type classification are depicted, grouped 
based on labels provided by the DLCST trial. For each nodule type, nodules 
classified by the deep learning system are ordered by increasing probability. As a 
consequence, atypical examples for each nodules type can be found on the left 
side of the figure, while typical examples can be found on the right side of the 
figure.
5.4  Discussion
The deep learning system produces a score by classifying an internal representation 
learned from raw data. In order to get insights on the kind of features learned by 
the network, we extracted an embedded representation of each nodule and 
applied multidimensional scaling to project the embedded representation onto a 
bidimensional plane. For this purpose, we applied the t-Distributed Stochastic 
Neighbor Embedding (t-SNE) algorithm108 to the output of the last fully-connected 
layer of the network. In this way, each nodule is represented by a feature vector of 
256 values. The result of the multidimensional projection is depicted in Figure 5.4, 
where close nodules have a similar representation in the network. Clearly defined 
clusters of nodules with similar characteristics can be identified. Examples are 
clusters of large solid nodules, calcified or perifissural nodules, but also groups of 
nodules of a particular class that was not used in this study, namely juxtapleural 
nodules.
 One of the clusters in the t-SNE representation shows a direct association 
between large solid nodules and spiculated nodules. Based on training data, the 
system implicitly learns that large solid nodules are likely to be spiculated 
nodules. This effect can be observed in the quantitative evaluation reported in 
Table 5.3, where spiculation has an F-measure of 62.7% when the system is 
compared with O4 on the subset of 162 nodules, while it decreases to an F-measure 
of 43.4% when all nodules are considered. The reduction in precision observed in 
the second experiment is therefore related to the presence of more large solid 
nodules that are misclassified as spiculated. This suboptimal behavior of the 
system can be compensated by increasing the amount of spiculated nodules in 
the training set, for example by including follow-up cases. Nevertheless, in the 
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clinical context of lung cancer screening, labeling large solid nodules as spiculated 
may not hamper the nodule workup, since large solid nodules without spiculation 
are also considered as suspicious lesions.
 The values of precision and recall per nodule type when the testALL set is 
classified with the 3-scale network are reported in Table 5.5. We can observe that 
the system tends to classify solid, calcified and non-solid nodules with high 
performance. As a consequence, since nodule type distributions are skewed (see 
Table 5.1), the overall accuracy for testALL is higher than for testOBS . The low value 
of precision and recall for part-solid and spiculated nodules in testALL corroborates 
what is observed for testOBS and can be compensated in the future by adding more 
training samples for underrepresented classes, therefore increasing the variability 
of nodule appearance in the learning procedure.
Table 5.3   Nodule classification performance in terms of accuracy and 
F-measure per nodule type. Results for each pair of human observer  
Oi vs. Oj and for observers versus the computer on the testOBS dataset  
(167 nodules) are reported. Averages of measures across observers 
and across computer-observers are also indicated. The additional 
class “not a nodule” is added to observers since they could exclude 
nodules during the observer study.
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O2 vs. Computer (3 scales) 66.2% 62.6% 82.4% 47.8% 72.7% 80.0% 56.4% –
O3 vs. Computer (3 scales) 67.7% 56.8% 85.1% 59.1% 78.3% 75.6% 60.9% –
O4 vs. Computer (3 scales) 72.8% 64.2% 88.9% 71.7% 80.0% 77.3% 62.7% –
Average 69.6% 61.1% 86.2% 61.3% 79.3% 73.8% 62.9% –
O1 vs. O2 66.0% 52.7% 84.0% 51.3% 79.2% 63.6% 83.3% 50.0%
O1 vs. O3 71.0% 55.0% 87.0% 66.7% 80.0% 81.5% 74.4% 40.0%
O1 vs. O4 72.8% 64.8% 90.9% 66.7% 71.7% 75.5% 89.4% 0.0%
O2 vs. O3 76.5% 74.7% 88.9% 61.5% 81.0% 77.3% 75.7% 66.7%
O2 vs. O4 72.2% 64.4% 88.5% 70.8% 71.1% 79.1% 73.2% 0.0%
O3 vs. O4 79.0% 68.4% 95.8% 71.1% 80.9% 90.6% 79.2% 0.0%
Average 72.9% 63.3% 89.2% 64.7% 77.3% 77.9% 79.2% 26.1%
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The performance of the system is within the inter-observer variability. This 
corroborates the effectiveness of the system at classifying nodules and also 
indicates that even experienced radiologists do not fully agree on nodule types. 
The concept of nodule type has been coined by radiologists, who have to differentiate 
opacities in CT scans according to their appearance and, most importantly, to 
their frequency of malignancy. The fact that there is no complete agreement 
among experienced radiologists implies that no gold standard for nodule type 
classification can be made, and that there will always be doubtful cases even in 
the training set. In this context, the range of variability within the one among 
Table 5.4   Comparison of classification performance on the testALL set  
(639 nodules) in terms of accuracy and F-measure when  
the considered methods are: (1) features based on pixel intensity  
of patches and linear SVM classifier, (2) features learned  from raw 
nodule patches using the unsupervised learning approach proposed 
in106 and linear SVM classifier, (3) the proposed deep learning 
approach using ConvNets working at 1, 2 and 3 scales. In these 
experiments, annotations from DLCST radiologists (O4) are considered  
as the reference standard.
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Intensity features + SVM 27.0% 4.1% 60.2% 0.0% 35.4% 26.7% 32.5%
Unsupervised features + SVM 39.9% 38.4% 32.0% 49.4% 59.2% 16.9% 39.5%
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Table 5.5   Precision and recall values for the 3-scale deep learning system  
tested the testALLset.
Solid Calcified Part-solid Nonsolid Perifissural Spiculated
Precision 89.2 88.9 43.6 87.4 78.4 32.7
Recall 82.2 82.8 64.9 87.4 60.4 64.3
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humans reached by the proposed system makes it the first suitable system to be 
integrated in workstations for automatic analysis of CT scans in lung cancer 
screening.
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Abstract
Introduction: To assess the performance of the Brock malignancy risk model for 
pulmonary nodules detected in a routine clinical setting.
Materials and methods: In two academic centers in The Netherlands, we established 
a list of patients aged ≥ 40 years who received a chest CT scan between 2004 
and 2012, resulting in 16,850 and 23,454 eligible subjects. Subsequent diagnosis of lung 
cancer until end of 2014 was established through linking with the National Cancer 
Registry. A nested case-control study was performed (ratio 1:3). Two observers used 
semi-automated software to annotate nodules. The Brock model was separately 
validated on each dataset using ROC analysis and compared to a purely size-based 
model.
Results: After the annotation process final analysis included 177 malignant and 
695 benign nodules for center A, and 264 malignant and 710 benign nodules for 
center B. The full Brock model resulted in AUCs of 0.90 and 0.91, while the size-only 
model yielded significantly lower AUCs of 0.88 and 0.87, respectively (p<0.001). 
At 10% malignancy risk, the threshold suggested by the British Thoracic Society, 
sensitivity of the full model was 75% and 81%, specificity 85% and 84%, positive 
predictive values (PPVs) were 14% and 10% at negative predictive values (NPVs) of 
99%. The optimal threshold was 6% for center A and 8% for center B, with NPVs 
>99%.
Discussion: The Brock model shows high predictive discrimination of potentially 
malignant and benign nodules when validated in an unselected, heterogeneous 
clinical population. The high NPV may be used to decrease the number of nodule 
followup examinations.
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6.1  Introduction
Several guidelines provide recommendations on how to manage pulmonary 
nodules based on the estimated risk of malignancy.18,25,30,109. Furthermore, several 
mathematical prediction models have been developed using both clinical and 
radiological criteria to help clinicians discriminate malignant from benign 
lesions.32–34.
 McWilliams et al. published the first risk calculator -known as the Brock or 
PanCan modelmathematically modeled to the outcome of screen-detected 
nodules in a large lung cancer screening trial17. The model achieved a high 
performance for predicting malignancy on a per nodule basis with an area under 
the curve (AUC) exceeding 0.90. Subsequently, validation of the model using lung 
cancer screening data from various studies, reached similarly high prediction 
values.74,75,80.
 In Lung-RADS (published by the American College of Radiologists), radiologists 
are encouraged to use the Brock model to decide on the follow-up procedure in 
lung cancer CT screening.30. Similarly, the British Thoracic Society (BTS) released 
guidelines for the investigation and management of pulmonary nodules in both 
screening and clinical settings, integrating the Brock model as a risk assessment 
tool for solitary non-calcified nodules. An empirically set threshold of a 10% 
malignancy risk in the Brock model guides the management for each nodule.18.
 Screening participants, in contrary to routine clinical subjects, usually have 
more small nodules, and are subject to specific inclusion and exclusion criteria 
(e.g. heavy smoking and age). Therefore, the high performance of the Brock model 
in screening cohorts may not automatically be extrapolated to a clinical setting. 
So far there is only one publication evaluating Brock in a clinical context. Al-Ameri 
et al.110 reported that the Brock model performed superiorly compared to other 
prediction models when applied on clinical data32,33. However, this study focused 
on a relatively small population (N = 244), excluded pure ground-glass nodules, 
and was conducted in a single center. Thus, the question remains whether the 
model performs similarly well in a clinical population compared to the screening 
setting in which it was designed. This study aims to validate the Brock model on 
an unselected, large and heterogeneous multi-center clinical population.
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6.2  Materials and Methods
Study population
We conducted our study at two academic centers in the Netherlands: University 
Medical Center Utrecht (center A) and Radboud University Medical Center 
Nijmegen (center B). In both centers the institutional review board waived the 
need for informed consent because of its retrospective design and the use of 
anonymized data.
 A list of all subjects aged 40 years and older who received a chest CT scan 
between January 2004 and December 2012 was established, comprising 16, 
850 subjects from center A and 23,454 from center B. Subsequently, the list of subjects 
was crossreferenced to the Netherlands Cancer Registry to acquire information on 
lung cancer diagnosis until the end of 2014. A total of 1095 and 2124 subjects were 
diagnosed with lung cancer at center A and B, respectively. For this study we only 
included lung cancer cases who had CT imaging available at least 2 months prior to 
the date of lung cancer diagnosis. By doing so we excluded prevalent lung cancers, 
for which imaging did not hold any longitudinal information on nodule evolution 
and future malignancy risk. The interval of 2 months was chosen arbitrarily to 
balance between longitudinal information and remaining study group size.
 Using the above-mentioned interval, a total of 228 subjects with lung cancer 
were included from center A, and 405 subjects from center B. A nested case-control 
design was applied using a case-control ratio of approximately 1:3111. “Cases” were 
defined as subjects with lung cancer diagnosis, while “controls” were defined as 
subjects without the diagnosis of lung cancer during follow-up. Controls were 
randomly selected from the total cohort of subjects without a lung cancer diagnosis 
and comprised a total of 684 and 1095 subjects for center A and B, respectively.
 Of all included subjects, both cases and controls, CT scans were retrieved from 
the PACS. In center A all scans were reconstructed with 1 mm thick slices. In center 
B the majority of the scans were reconstructed with 3 mm thick slices. For controls 
the oldest available CT was collected. For cases all diagnostic CT scans were 
obtained. Additional exclusions prior to the start of the annotation process were 
mainly due to retrieval errors and insufficient study quality. In total, an extra 155 
cases and 612 controls were excluded. Figure 6.1 shows the study population 
selection flow-chart.
Annotation process
Dedicated in-house software with computer-aided detection (CAD) of both solid 
and subsolid pulmonary nodules was used for the annotation process (CIRRUS 
Lung Screening, DIAG Nijmegen, the Netherlands). All non-calcified nodules 
4 mm or larger were semi-automatically annotated by one observer in each center 
Validation in a clinical setting | 109
6
Figure 6.1  Flow-chart of inclusion before the start of the annotation process.
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(OMM and ETS with 7 and >20 years of experience in chest CT). Scans were 
excluded if subjects were mechanically ventilated, as were scans in which the 
observer considered a significant part of the lung not assessable (e.g., incomplete 
data, presence of extensive consolidation, and severe breathing artefacts).
 Observers were instructed to first go through any CAD candidates. True- 
positive CAD candidates were accepted and false-positive CAD candidates were 
removed. Subsequently, each scan was visually checked for additional nodules 
primarily missed by the CAD. Effective nodule diameter and nodule volume were 
measured semi-automatically using different thresholds for nonsolid and solid 
nodule components. Nodule type (solid, part- solid, or nonsolid), spiculation 
(yes/no), and affected lobe were recorded per nodule. In all scans, presence of 
emphysema was visually assessed (yes/no).
 In the group with lung cancer confirmed by the National Cancer Registry, 
the date of diagnosis (incidence date) as well as the affected lobe were available. 
We aimed at identifying each malignancy in the available CT datasets by linking 
all nodules in the affected lobe across all follow-up scans and assessing nodule 
morphology and growth pattern. For evaluation in this study, we used the oldest 
available CT scan on which the lesion was visible. A score of 0 to 4 was applied to 
rate the degree of certainty of the above-mentioned process. Score 0 referred to no 
visible lesion in the tumor-bearing lobe. Score 1 referred to a nodule in the 
tumor-bearing lobe without any signs of malignancy (i.e. highly unlikely to 
represent the cancer). Score 2 referred to an equivocal lesion in the tumor-bearing 
lobe (i.e. no decision possible). Score 3 referred to a suspicious lesion in the 
tumor-bearing lobe, but there was no CT scan within 1 month of the incidence 
date available for definite confirmation (i.e. lesion highly likely to represent the 
lung cancer). Score 4 referred to a suspicious lesion in the correct lobe and an 
available CT scan within 1 month of the incidence date (i.e. confirmation of the 
lung cancer). Lesions with a score of 0, 1, or 2 were excluded. Hence, only score 3 
and 4 lesions were included in our analysis, as these were considered to securely 
represent lung cancers. In controls, nodules were annotated on the oldest CT scan. 
All nodules - irrespective of being solitary or multiple per scan - were included in 
the analysis.
Statistical analysis
The original Brock publication calculated four models using different sets of input 
criteria. In the present study the two models that included spiculation as variable 
were applied to the subjects of center A and B separately; i.e. the full (2b) and 
parsimonious (1b) Brock model17. According to standard nested case-control 
analysis,111,112 the randomly selected subsets of controls were inflated to simulate 
a full cohort, resulting in 11,770 and 12,779 subjects, respectively. Family history 
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was not known in our study population due to the retrospective study design and 
was therefore set to zero. 
 For both validation cohorts, discriminative performance of the Brock model 
was assessed using receiver operating characteristic (ROC) analysis, resulting in 
areas under the curve (AUC) as a performance indicator. A third simple logistic 
regression model was applied using only nodule size as predictor of lung cancer 
risk. Differences in discriminative performance were tested between the three 
models by AUC comparison according to de Long et al.113. Sensitivity, specificity, 
positive predictive value (PPV), and negative predictive value (NPV) were 
calculated at a threshold of 10% malignancy risk, the threshold used in the BTS 
guideline flowchart to select pulmonary nodules for more intense diagnostic 
work-up. In addition, we determined performance at the optimal threshold of the 
ROC curve (i.e. the point on the ROC curve closest to the point where sensitivity 
and specificity equal 100%). For comparison, we report performance of the 
size-only model at the specificity achieved by the full Brock model at a risk 
threshold of 10%.
6.3  Results
Subject and Nodule characteristics
In total, 441 nodules were given a malignancy score of 3 or 4 (177 in center A and 
264 in center B). A total of 1405 benign nodules (695 in center A and 710 in center B) 
were found in controls, with a median follow-up of 70 months and 76 months, 
respectively. For cases, the median time between the annotated CT and incidence 
date was 4 months and 2 months for center A and B, respectively.
 On average, cases were older than controls. The majority of benign and 
malignant nodules were solid (83%-88%). Malignant nodules were larger than 
benign lesions, were more likely to be located in the upper lobes and were more 
often spiculated. In center A, a higher prevalence of females was seen (50% versus 
41%, compared to center B), as well as a higher prevalence of emphysema (66% 
versus 44%). Table 6.1 lists the study population characteristics for the two centers.
Validation of the Brock model
The AUCs of the full Brock model were 0.901 and 0.911, respectively. This significantly 
exceeded the parsimonious model: 0.894 and 0.881, respectively (p < 0.05) (Figures 6.2 
and 6.3). At a 10% malignancy risk threshold, sensitivity per center was 75% and 
81% (PPV = 10% and 14%), and specificity was 86% and 84% (NPV = 99% and 99%). 
The optimal threshold was 6.0% in center A (sensitivity of 84% and specificity of 
80%) and 8.2% in center B (sensitivity of 86% and specificity of 80%).
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When using only size to predict the lung cancer risk an AUC of 0.876 and 0.866 was 
found for center A and center B. These AUCs were significantly lower (p < 0.001) 
compared to both the full and the parsimonious model (Figures 6.2 and 6.3). 
Discriminatory performance is summarized in Table 6.2.
Table 6.1  Subject and nodule characteristics.
Center A Center B
Benign (695) Malignant (177) Benign (710) Malignant (264)
Age in years, mean (SD) 61 (12) 65 (9) 63 (10) 64 (9)
Sex
Male 434 (62) 89 (50) 413 (58) 157 (59)
Female 261 (38) 88 (50) 297 (42) 107 (41)
Emphysema
No 436 (63) 61 (34) 555 (78) 148 (56)
Yes 259 (37) 116 (66) 155 (22) 116 (44)
Nodule type
Nonsolid 84 (12) 4 (2) 50 (7) 11 (4)
Part-solid 23 (3) 26 (15) 42 (6) 20 (8)
Solid 588 (85) 147 (83) 617 (87) 233 (88)
Nodule size (mm)
Median 5.2 17.2 8.0 20.3
IQR 4.3-8.6 11.5-27.8 5.9-11.6 13.7-31.2
Location
Lower lobe 368 (53) 60 (34) 378 (53) 99 (37)
Upper lobe 327 (47) 117 (66) 332 (47) 165 (63)
Nodule count
Median 4 3 6 2
IQR 2-5 1.5-4 2-11 1-3
Spiculation
No 694 (99.9) 156 (88) 702 (99) 193 (73)
Yes 1 (0.1) 21 (12). 8 (1) 71 (27)
IQR, inter-quartile range (from 25th to 75th percentile); SD, standard deviation.
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6.4  Discussion
In the past few years, a lot of attention has been paid to optimizing the 
management of screen-detected pulmonary nodules, motivated by the reduction 
of lung cancer mortality found in the National Lung Screening Trial (NLST)10. 
Especially in a screening setting where the majority of nodules seen on CT are in 
fact benign, patient management should be personalized using individual nodule 
risk estimations to save radiation, workload, unnecessary psychological stress and 
financial expenses.
 The same is also true for routine clinical care, not only because of the increasing 
use of CT and the related increase in the number of incidentally detected 
pulmonary nodules, but also because of the increase in shared decision making 
by patients and clinicians38,114. Pooling the results of several studies reported a 
mean nodule prevalence of 13% for incidental nodules compared to 33% for 
screen-detected nodules with a comparable lung cancer prevalence of 1.5% and 
1.4% respectively18. Although the reported prevalence of nodules is smaller in 
Figure 6.2  Results of the Brock validation in Center A of the full and 
parsimonious Brock model (p = 0.03) as well as the size only model (p < 0.001 
compared to full and parsimonious).
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a clinical context than in a screening, numbers are substantial and represent a 
significant cause for follow-up CTs for eventually benign nodules.
 Mathematically validated risk calculators could be used to help to guide the 
management of pulmonary nodules. The Brock model, developed by McWilliams 
et al8, has demonstrated an excellent capacity to discriminate between benign 
and malignant in screen-detected nodules, and its use is incorporated in nodule 
management guidelines for both screening and clinical use18,30, despite validation 
in clinical subjects was until now only performed once in a small single center 
study110.
 In this study, we validated the Brock model outside a screening setting, using 
a large clinical dataset from two academic centers. In our unselected and hetero- 
geneous population -even without the restrictions of the Brock model exclusion 
criteria (e.g. previous lung cancer or certain co-morbidities) - the model achieved 
AUCs greater than 0.90 in both data sets. This shows that the malignancy risk 
calculator is also applicable for incidentally found nodules in daily-routine clinical 
care, although the performance is somewhat lower than in a screening setting.
Figure 6.3  Results of the Brock validation in Center B of the full and 
parsimonious Brock model (p < 0.001) as well as the size only model (p < 0.001 
compared to full and parsimonious).
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Previously, the Brock model was externally validated on screening data from the 
Danish Lung Cancer Screening Trial and the NLST, showing AUCs ranging 
between 0.826 and 0.96374,75. White et al.74 found the threshold of 10% malignancy 
risk to be optimal, with a corresponding sensitivity, specificity, PPV, and NPV of 
85.3%, 93.9%, 27.4%, and 99.6%, respectively. We found similarly high results for 
the NPV (99%), indicating that a risk score < 10% reliably indicates that a nodule is 
benign. However, the sensitivities (75% and 81% versus 85.3%), specificities (86% 
and 84% versus 93.3%), and PPVs (10 and 14% versus 27.4%) in our clinical cohorts 
were inferior, emphasizing the different characteristics and challenges of a 
clinical population compared to a more homogeneous screening population.
 Recently, the Brock model was validated on a clinical UK population110. 
The AUC obtained was 0.90 in a restricted single-center cohort (N = 154) after 
applying the same exclusion criteria used in the Brock study. Results were worse 
(AUC = 0.868) when the model was validated on the full cohort (N = 244). In our 
study, we did not apply any exclusion criteria besides image quality issues and 
age below 40 years. Moreover, we included all nodule types, while pure-ground 
glass nodules were excluded in the UK study110.
Table 6.2  Brock model performance in center A and B.
AUC Risk threshold Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
Center A
Brock (Full) 0.901 BTS: 10 75 86 10 99
Optimum: 6.0 84 80 8 100
Brock (Pars.) 0.894 BTS: 10 76 85 9 99
Optimum: 9.0 80 84 9 100
Size only 0.876 Eq. spec.* 10.4 71 86 9 99
Optimum 4.7 86 78 7 100
Center B
Brock (Full) 0.911 BTS: 10 81 84 14 99
Optimum: 8.2 86 80 13 99
Brock (Pars.) 0.881 BTS: 10 80 77 10 99
Optimum: 13.8 75 85 15 99
Size only 0.866 Eq. spec.* 3.8 71 84 13 99
Optimum 2.8 80. 79 11 99
AUC = area under the curve. PPV = positive predictive value. NPV = negative predictive value. 
Eq. spec. = equal specificity. BTS = British Thoracic Society. Pars = parsimonious.
* = fixed to equal specificity as the full Brock model at 10% malignancy risk.
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It has to be emphasized that the model achieved similar results in both validation 
cohorts of our study, despite that CT data was reconstructed with 1-mm thick 
slices in center A and mostly 3-mm thick slices in center B, which resulted in 
different spatial resolution and different accuracy for the assessment of nodule 
type, spiculation, and nodule size.
 Although significant, the AUCs show relatively small differences (1-5%), and 
clinical relevance of these differences therefore has to be interpreted with caution. 
Still, statistically our study showed that nodule size plays a major role. Our study 
showed that nodule size plays a major role. Although NPV was the same (99%) 
when compared to the parsimonious and full Brock model at equal specificity, 
AUC and sensitivity of the size-only model was notably lower. This means that 
a size-only model is well capable of indicating benign nodules based on a small 
nodule size, but using only nodule size to predict malignancy shows inferior 
performance.
 Our study has a number of limitations. First, data on lung cancer diagnosis 
was obtained through the National Cancer Registry, but did not include CT data. 
We therefore had to use the individual lobe location and incidence date to 
determine the nodule corresponding to the cancer. Only nodules which were 
assigned a high level of confidence for representing the known lung cancer were 
included in the study. This may have introduced a small bias towards more 
obvious malignancies. Second, for the benign nodules we relied on the outcome 
data that they did not develop into a malignancy over a median follow-up period 
of 70 and 76 months in center A and B, respectively. This might have led to some 
misclassification in non-solid nodules, where development into malignancy 
might take numerous years19. However, since the National Cancer Registry 
archives all malignancies irrespective of hospital in the Netherlands and given 
that the median follow-up period was relatively long, we consider the outcome 
data reliable. Third, due to the retrospective nature of this study certain clinical 
information of the study population was not available; e.g. smoking behavior, 
symptoms, and family history. However, the only parameter that might have had 
an impact in our study, since it is included in the Brock model, is family history. 
Nevertheless, since family history did not belong to the group of important input 
factors in the original Brock model we consider its influence on our results to be 
limited. Last, a certain percentage of controls was excluded, mainly because of 
image quality issues. This may have led to a selection bias. However, given the 
unselected heterogeneous data set and randomly selected controls, we consider 
the effect of little importance. 
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In conclusion, we are the first to validate the Brock risk prediction model in an 
unselected, large and heterogeneous multi-center clinical population. Our results 
indicate that the model has a very high negative predictive capacity outside a 
screening setting. Furthermore, it mirrors the findings from lung cancer screening 
literature as having a high discriminatory performance, although somewhat 
inferior. Therefore, we conclude that the Brock risk prediction model is capable to 
contribute to a personalized risk-dependent lung nodule management outside a 
screening setting, in an unselected, heterogeneous clinical population. The assumed 
extrapolation by the guidelines applying the Brock model in clinical subjects 
seems legitimate.

General Discussion
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General Discussion
In this chapter, we discuss the contributions and advances we have made to provide 
an answer to questions regarding the malignancy estimation of subsolid nodules. 
We also address future work to further improve the management of subsolid nodules.
Should the radiologist recommend a short-term follow-up scan 
when she or he detects a screen-detected subsolid nodule?
One of the most important things that radiology residents learn early in their 
training is to check the patient’s medical history. Was the nodule already visible 
in a prior scan, and if so, has it grown? The reason is that longitudinal information 
provides additional knowledge such as lesion persistence, growth and morphological 
change over time. If no previous scan is available, one of the most common next 
steps is to request a follow-up scan. This is however associated with radiation dose, 
possible patient anxiety, extra work for the radiologists and financial expenses.
 In chapter 1 we started off investigating if there are features that can be used 
to distinguish transient from persistent subsolid nodules, therefore avoiding 
unnecessary short-term follow-up scans. One of the most common reasons for 
new subsolid nodules are focal infections, thus lesions which are transient and 
vanish after a short period of time, often even without treatment. A prospective 
reliable distinction between those transient infectious and persistent non- 
infectious subsolid nodules would therefore be useful. However, are radiologists 
able to reliably differentiate these two categories based on visual assessment of 
CT morphology? We found that even in subsolid nodules larger than 10 mm, the 
visual capacity of experienced radiologists is only moderate. While 68 (40%) of 
172 subsolid nodules were correctly classified by all 4 radiologists, 37 (22%) nodules 
were misclassified by all four observers. We concluded from those results that 
assessment of CT morphology alone is not sufficient to generally leave out a 
short-term follow-up scan and to rely on visual analysis alone.
 In chapter 2 we did a similar observer study but with a different focus: 
we asked the radiologists to differentiate between the malignant and benign 
character of subsolid nodules. Unlike other guidelines such as the Fleischner 
Society and British Thoracic Society, Lung-RADS includes an extra category, which 
is based on the ’Fingerspitzengefühl’ of a radiologist. This category is named ’4X’. 
The inclusion of this special class in Lung-RADS allows the reader to upgrade a 
nodule from lower risk categories (3, 4A or 4B) based on ’additional features or 
imaging findings that increase the suspicion of malignancy’. As a result, nodules in 
category 4X will receive a more intense or even invasive workup, such as PET-CT 
or biopsy. In this study, we asked the readers to upgrade suspicious nodules to 
Lung-RADS 4X. It turned out that radiologists were good at correctly picking 
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suspicious subsolid nodules: the prevalence of malignant lesions was much 
higher in category 4X compared to size-based Lung-RADS categories 3, 4A or 4B 
(53% versus 9% - 23%). This finding indicates that radiologists have a certain 
gestalt in their mind defining lesions as suspicious for malignancy. Unfortunately, 
the readers also falsely upgraded benign lesions, with false positive rates ranging 
from 7 to 19%. Interestingly, on average, one-third of these benign falsely upgraded 
nodules were again transient. In conclusion, our study confirmed the benefit of 
category 4X, but as a consequence of the finding that a substantial number of 
falsely upgraded lesions were transient, we also proposed to include a short-term 
follow-up for category 4X to avoid unnecessary workup of transient subsolid 
nodules.
 In chapter 3 we looked at the possible overestimation in the highest size-based 
risk category of Lung-RADS (4B) and the possible underestimation in the lowest 
risk category of Lung-RADS115. The highest size-based category (4B) is prone to 
overestimation of malignancy risk because of the morphological overlap with 
transient (benign) nodules and the lack of short-term follow-up scan to confirm 
persistence. As a result, patients could receive unnecessary invasive diagnostics. 
Though we did not find a general overestimation of the calculated malignancy 
risk of category 4B nodules, an interesting finding was that no less than one-third 
of the subsolid nodules in this category were found to be transient. A short-term 
follow-up could easily help in excluding these lesions from unnecessary invasive 
workup.
 The use of CT scans has skyrocketed in the last decade and continues to rise38. 
At a jointly organized international workshop by the European Union and 
International Atomic Energy Agency in 2012, it was concluded that more than 20% 
of requested examinations may not be appropriate, leading to unnecessary costs 
and exposure to radiation in patients115. In that context, proposing additional 
short-term follow-up CT scans has to be well justified. In this thesis, we found 
strong evidence in three of our studies supporting the additional value of a 
short-term follow-up CT to discard transient benign subsolid nodules from more 
invasive workup. Therefore, we believe that adding a short-term follow-up scan 
would be beneficial in the Lung-RADS guidelines, following the example of other 
guidelines such as the British Thoracic Society.
What should be the interval for a short-term follow-up of  
an incidentally detected subsolid nodule?
Having answered our previous question affirmatively, the next question is what 
would be the appropriate interval for initial follow-up. As mentioned before, the 
Lung-RADS guidelines do not include a short-term follow-up scan to confirm 
persistence, in contrast to the British Thoracic Society and the Fleischner Guidelines. 
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The former includes a short-term follow-up scan at 3 months to confirm persistence 
of both nonsolid and part-solid nodules18. The latter, recommends part-solid 
nodules to receive a follow-up at 3-6 months while nonsolid nodules have an 
initial follow-up at 6-12 months.
 The differences of time intervals are based on the thought that earlier 
follow-up indeed provides information about persistent versus transient nodule 
character. Nevertheless, it does not provide any additional longitudinal information 
on the development of persistent nodules. At the same time, it is unlikely to affect 
the outcome of indolent nonsolid nodules25. Therefore, it could be argued that a 
first short-term follow-up is only needed for so-called high-risk nodules that 
would undergo more invasive workup if persistent. For low-risk nodules, however, 
short-term proof of prevalence is less important unless for example requested by 
the patient for psychological reasons. This important aspect of patient preference 
and the concept of shared decision responsibility is partially addressed by the 
new Fleischner guidelines: They provide ranges of follow-up times rather than 
fixed time intervals.
Does the size threshold for nonsolid nodules need to be lowered?
Lung-RADS uses a relatively high size threshold for nonsolid nodules in category 2, 
which describes the nodules with a very low likelihood of becoming invasive 
cancer and thus a regular annual screening with low-dose CT is recommended. 
The threshold in Lung-RADS is < 20 mm, higher than the threshold of 5-6 mm used 
by the British Thoracic Society and Fleischner Society guidelines18,25. The American 
College of Radiology has indicated that the threshold is even planned to be 
increased to 30 mm in the next version of Lung-RADS. Indeed, literature studies 
have described that nonsolid nodules rarely manifest as invasive cancers or 
undergo a stage shift and can thus be safely followed-up with CT57,59. On the other 
hand, several reports, especially from Asian studies, have shown nonsolid nodules 
to be invasive cancers35,36,116. We know from an earlier report that only fair 
agreement has been found among pathologists for distinguishing invasive from 
in-situ patterns in adenocarcinomas, which might partially explain the 
differences117. The statement that nonsolid nodules are mostly indolent therefore 
remains unclear.
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On October 2016, a poem called “I long to be king” was released in Chest, written by 
a pulmonologist from Shanghai118:
I am a ground-glass opacity (GGO) in the lung,
A vague figure shrouded in mystery and strangeness,  
Like looking at the moon through clouds,
Like seeing beautiful flowers in the fog. 
(. . . )
From tiny to strong,  
From humble to arrogant.
None cared when I was young,  
But all fear me we when full grown.
In this poem the author describes the importance of understanding nonsolid 
(ground-glass) nodules and its potential growth into invasive adenocarcinomas. 
He urges clinicians to take subsolid nodules seriously and describes the increase 
of the detection rate of ground-glass nodules in China, emphasizing the need for 
physicians to not underestimate these nodules.
 Indeed, in chapter 3 we found nonsolid nodules smaller than 20 mm in size 
that turned out to be invasive. We calculated that lowering the threshold to 15 or 
10 mm would catch some lesions that would eventually turn invasive, but this 
would be at the expense of numerous benign nonsolid lesions getting earlier 
follow-up. Thus, lowering threshold would not be ideal. Instead, we advise an 
extension of Lung-RADS to include the option for upgrading category 2 lesions to 
category 4X. As shown in chapter 2, radiologists are well capable to correctly 
select malignant lesions. Though this study included Lung-RADS 3 and 4 with 
nonsolid nodules > 20 mm, we expect that radiologists will also be able to have 
similar results in nonsolid nodules < 20 mm. With this modification of the 
guidelines, the management of nonsolid nodules would be enhanced allowing for 
an intensified workup of suspicious nonsolid nodules. In this context, it has to be 
noted that the distinction between pre-invasive (AIS, MIA) from invasive lesions 
is important to avoid overtreatment of actually indolent pre-invasive lesions in 
subjects in which outcome would not be limited by treatment of these rather 
indolent lesions, but by concomitant health issues.
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Are morphologic features useful in the discrimination of benign 
and malignant subsolid nodules?
In chapters 1 and 2 we analyzed the visual ability of radiologists to discriminate 
transient from persistent and malignant from benign subsolid nodules. In both 
studies, observers were asked to indicate the morphologic features that triggered 
their decision using a predefined questionnaire. However, in both studies observer 
variability was too large to be able to define specific morphologic features that 
would be generally applicable. In chapter 2 we showed that radiologists have 
a remarkable ’Fingerspitzengefühl’ when it comes to correctly selecting the 
malignant nodules, however, we failed to pinpoint the morphologic findings 
responsible for that.
 Similarly, two earlier studies showed that even a basic decision such as 
the classification of nodule type (solid versus nonsolid and part solid) is prone 
to substantial inter-reader variability even among experts37,47. Intra-observer 
agreement was also found to be as low as 0.57 (’moderate’) in one study47, 
inter-observer agreement varied from 0.51 to 0.62. Authors from both studies 
emphasized that variability in nodule classification has a considerable impact on 
nodule management since all current management strategies use nodule type as 
important input factor37,47.
 There are also previous studies that looked into predictive morphologic 
features for persistency or malignancy in subsolid nodules27,28,35,42,46,69,119. For 
example, lesion border was investigated in almost all studies and yielded variable 
results. In some studies lobulated borders or spiculated borders were found to 
be associated with malignancy35,46,69, while another study27 found a lobulated 
border to be predictive of transient subsolid nodules. Two studies found ’smooth’, 
’notched’ or ’ill-defined’ borders to be predictive of pre-invasive or transient 
lesions28,119. Lesion size, which is more straight-forward and quantitative, was 
also a feature investigated in the studies. Interestingly, even the results for size 
were not uniform: the majority of the studies found a larger size to be associated 
with malignancy35,46,69,119 or persistence42, while two studies found a larger size 
to be associated with transient subsolid nodules27,28.
 We conclude that according to results from this thesis and other studies, it is 
not possible to visually identify generalized and reproducible morphologic 
features. Hence, computerized texture analysis with the latest machine learning 
algorithms (deep learning) might likely be the solution to define reliable predictive 
morphologic features in subsolid nodules and achieve robust nodule type 
classification. Earlier studies have investigated these possibilities42,120,121, but they 
only included small samples and merely analyze a handful of basic first-order 
statistics, such as mean density and entropy. However, in chapter 5 we showed 
the results of a deep learning based computer system for the classification of 
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nodule type. With deep learning networks it is possible to achieve multiple levels 
of representation at a higher more abstract level, allowing to implement complex 
functions31. The deep learning system presented in chapter 5 surpasses the 
classical machine learning approaches and is within inter-observer variability 
among four experienced human observers. It is expected that many more 
revolutionary deep learning solutions will be proposed in the near future, and 
could aid radiologists in the management of subsolid nodules by automatically 
analyzing morphologic features.
Is growth a useful parameter in a malignancy prediction model  
for subsolid nodules?
Our results suggested that radiologists cannot reliably identify morphologic 
features to distinguish benign from malignant subsolid nodules. In recent years, 
a lot of research has been carried out in developing mathematical prediction 
models to aid radiologists in this task. Since they have been mostly developed 
using screening datasets, their performance has been tested on datasets with 
mostly solid nodules (Brock model)17,110. In chapter 4 we validated the Brock 
malignancy risk calculator model for the first time on a large data set of only 
subsolid nodules, finding that it has a similar high discriminative capacity. For 
the first time, we could demonstrate that in subsolid nodules - persistent after one 
year - adding growth in the model leads to a further significant improvement of 
the discrimination between benign and malignant. This was an interesting 
finding, as subsolid nodules are known for their indolent behavior and slow 
growth. Nevertheless, the little growth after only one year was reliable enough 
that - when included in the mathematical model - it significantly increased 
discrimination capacity. In this study, growth was assessed using semiautomatic 
volumetry and not manual measurements, which might have played a role to 
reliably quantify the small differences in volume of the total lesion.
 This predictive information could eventually be used to adapt follow-up 
period and interval to individual nodule risk, thus improving screening efficiency 
in its whole. The exact follow-up period and interval for subsolid nodules are still 
under debate. The Fleischner Guidelines recommend continuing a CT scan every 2 
years or 1 year after the initial scan over a period of 5 years for nonsolid and 
part-solid nodules with a solid component smaller than 6 mm, respectively. This 
is based on literature showing an average of 3-4 years to establish growth or to 
diagnose a developing invasive carcinoma36,59,122–124. The British Thoracic Society 
has a different approach and recommends to continue follow-up at 1, 2, and 
4 years from baseline for subsolid nodules with a low malignancy probability 
(< 10%) in the Brock model.
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Our results show that including information after one year, already improves the 
Brock model significantly. Future research will have to find out whether inclusion 
of short-term growth information in the Brock model will help to further 
individualize follow-up intervals not only according to malignancy probabilities 
but also biological behavior in terms of growth tendency.
Can we transfer the knowledge about nodule management  
from screening to a clinical setting?
In the past few years, multiple studies about pulmonary nodules have been 
conducted using databases from screening studies6,10,12,13,17,66,72,75. Basically all 
published recommendations on nodule management are based on evaluations of 
screening studies18,25. However, the inclusion of subjects in a screening study is 
different from a typical clinical patient. Subjects in screening studies are selected 
within a specific age range and dependent on smoking history, exclusion criteria 
such as history of lung cancer and other comorbidities are usually applied. 
Screening subjects do not have symptoms, whereas clinical patients present 
themselves with respiratory or also non-respiratory symptoms. While the clinical 
diagnosis of lung cancer is still frequently in a late stage, radiologists are increasingly 
confronted with the incidental finding of a pulmonary nodule that may be benign 
but potentially may also represent early cancer. Therefore, it is very important to 
evaluate to which extent the performance of management rules developed on 
the base of screening studies is reproducible in a clinical population.
 Mets al.125 investigated the presence and morphology of subsolid nodules in a 
non-screening setting. They found the same previously reported characteristics 
and associated factors of subsolid nodules that were reported in screening studies, 
such as the preference of upper lobe location and the tendency for growth in 
part-solid nodules. Another study by Mets et al.126 revealed that also in a clinical 
setting perifissural nodules are associated with a benign character, confirming 
the results of two previous screening studies86,127. This strengthens the finding 
made previously that perifissural nodules can be left out from further follow-up 
workup if morphology is typical. These are two examples where results from 
screening studies could be reproduced in a clinical setting.
 The Brock model was developed on screening data, but has been adopted by 
the British Thoracic Society guidelines as a tool for nodule risk estimation for both 
screening and clinical subjects18,30. However, thus far only a single and rather 
small single-center study by Al-Ameri et al. have evaluated the performance of 
the Brock model in a clinical patient population and reported high-performance 
values110. The study group was small (N = 244) and nonsolid nodules had been 
specifically excluded. In chapter 6, for the first time, we report the results of 
validating the Brock model on two large data sets of two academic centers. 
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Performance values - indicated as AUCs of 0.90 - were high in both academic 
centers, confirming that the Brock model is an appropriate and useful nodule risk 
tool also in a heterogeneous, clinical population. The performance was somewhat 
lower as in a screening setting which can be explained by the less strict 
discrimination of small benign and larger suspicious nodules. Interestingly size 
alone performed significantly lower underlining the value of the additional input 
factors such as lobe location, presence of emphysema and nodule type.
 In chapter 6 we only considered the information of one scan and did not 
include longitudinal information. However, in chapter 4 we described our finding 
that adding growth to the Brock model in persistent subsolid nodules lead to a 
significantly improved discrimination of malignant from benign nodules. Since 
in a clinical population follow-up scans are often performed, information on 
short-term growth, if available, is likely to add significantly to the performance of 
the Brock model also in a clinical setting.
...and lastly: can we select patients at high-risk of developing cancer 
from subsolid nodules?
Though much has been uncovered about subsolid nodules in the past years, there 
are still challenges to overcome. One of the main issues is whether it is possible to 
select people at high risk of developing lung cancer from subsolid nodules for 
screening programs. Numerous risk models have been developed to predict 
individual risk for developing lung cancer by using patient characteristics and 
other clinical risk factors as input parameters128–130. The better the selection of 
subjects at risk, the more effective such screening is. A recent review aimed to 
externally validate and compare nine risk models. They found that risk models 
were superior to currently recommended selection criteria from screening trials, 
which thus far did not use any mathematical validation models131. In general, all 
models considered age, aspects of smoking exposure or asbestos exposure as risk 
predictors. However, characteristics of patients with subsolid nodules (especially 
nonsolid nodules) are different from patients with ’typical solid lung cancer’. In 
fact, characteristics are quite the opposite: patients are usually relatively young, 
non-smoking women, and of Asian origin132. These risk models would therefore 
not apply perfectly to these patients. At present we do not know what causes the 
development of subsolid nodules in this population. Is it the cooking fumes as 
some suggest132? Is it caused by genetic predisposition or something we yet have 
to find out? Future studies that also include ethnical and genetic aspects will 
hopefully open the way to develop models that can select people at high risk of 
developing malignant subsolid nodules. This next milestone would not only 
notably improve care for lung cancer patients, but also help in understanding 
subsolid nodules even better.
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Summary
Subsolid nodules represent a spectrum from pre-invasive to invasive adeno-
carcinomas. To make the differentiation, management guidelines advise long-term 
follow-up for many years  to determine longitudinal changes. Risk prediction 
models would help in guiding the process. In this thesis we address a few issues 
with respect to human and computer-enhanced characterization and risk 
prediction of subsolid nodules that give more insight in optimizing and ideally 
 individualizing management of this subset of lesions. Since subsolid nodules are 
seen less frequent than solid nodules, we took the advantage of the largest publicly 
available screening data base of the NLST for our studies.
 While the first studies are focusing on screening data sets, the last study made 
the step over to a large clinical data set, evaluating whether models developed 
and evaluated primarily using screening data are also valid for clinically seen 
nodules. Both visual assessment of experienced radiologists as well as computer 
enhanced analysis were subjects of evaluation. In the following the summary is 
divided into three parts:
1. Visual assessment of subsolid nodule characteristics
2. Mathematical prediction models and automatic classification of subsolid nodules
3. Risk prediction models for pulmonary nodules: transition from screening to 
clinical setting
Part I. Visual assessment of subsolid nodule characteristics
In this part we conducted two observer studies regarding subsolid nodule 
management. The first step after detecting a subsolid nodule is trying to answer 
whether it is a transient or persistent nodule. Knowing that a subsolid nodule is 
transient means that a patient does not need any further (invasive) follow-up. Since 
we know subsolid nodules are frequently benign, most often infectious, identifying 
morphologic features that can distinguish between transient and persistent 
subsolid nodules would reduce follow-up scans and improve patient care.
 In chapter 1 we evaluated whether and to which extent experienced radiologists 
are able to visually correctly differentiate transient from persistent subsolid 
nodules from a single CT examination. We also analyzed if there were any CT 
morphological features that radiologists use to make this differentiation. 
Eighty-six transient and 135 persistent subsolid nodules were selected from the 
National Lung Screening Trial (NLST) database. Four experienced radiologists 
visually assessed a predefined list of morphological features and gave a final 
judgment on a continuous scale (0-100).
 On average, observers were able to differentiate transient from persistent 
subsolid nodules larger than 10 mm by visual assessment with an area under the 
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curve (AUC) of 0.75 (95% CI 0.67-0.82). Nodule type, lesion margin, presence of 
a well-defined border, and pleural retraction showed significant differences 
between transient and persistent lesions in two observers. None of the features 
were found to be significant for all four observers. Agreement for morphological 
features varied from 47% to 95%. From this study we concluded that the visual 
capacity of experienced radiologists to differentiate persistent and transient 
subsolid nodules is only moderate in subsolid nodules larger than 10 mm. 
Performance of the visual assessment of CT morphology alone is therefore not 
sufficient to generally abandon a short-term follow-up for subsolid nodules.
 In chapter 2 we took it one step further and looked into the use of the category 
4X of the Lung-RADS nodule management guidelines. Lung-RADS introduced a 
special category 4X, which unlike the other size-based categories, is based on 
the judgment of the radiologists. Radiologists are allowed to upgrade category 3, 
4A and 4B lesions into this category when they find suspicious features.
 Purpose of this study was to show the added value of Lung-RADS 4X over 
Lung-RADS 3, 4A and 4B for differentiating between benign and malignant 
subsolid nodules. Six experienced chest radiologists were independently asked to 
determine which nodules to upgrade to 4X. We compared malignancy rates of 
pure size-based categories to category 4X. The observers promoted between 15% 
and 24% of the subsolid nodules to 4X. The malignancy rate for 4X varied from 
46% to 57% per observer, which was substantially higher compared to the 
malignancy rates of category 3, 4A and 4B subsolid nodules without observer 
intervention (9%, 19%, and 23%, respectively). On average the false positive rates 
of 4X were 7% for subsolid nodules in category 3, 7% in 4A and 19% in 4B. From 
these upgraded benign lesions, on average 27% were transient.
 We concluded that the inclusion of a 4X category for suspicious lesions in a 
nodule management tool is of added value and results in high malignancy rates 
in the hands of experienced radiologists. Moreover, the addition of short-term 
follow-up for lesions in category 4X would be useful to assess the transient 
character, and thus substantially decrease the number of falsely upgraded benign 
subsolid lesions.
 In chapter 3 we zoomed into the lowest and highest risk categories of Lung- 
RADS. Lung-RADS 2 has a relative high threshold for nonsolid nodules (< 20 mm), 
and is therefore susceptible to possible underestimation of malignancy probability. 
The highest risk category 4B contains all part-solid nodules with a solid core 
≥ 8 mm. Lung-RADS does not include any short-term follow-up to confirm 
persistence, and hence, its category 4B is prone to overestimation of malignancy 
probability.
 Therefore in chapter 4 we quantified and compared malignancy rates for 
Lung- RADS 2 and 4B subsolid nodules on a nodule base. We identified all baseline 
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subsolid nodules eligible for Lung-RADS 2 and 4B in the NLST database. A slightly 
underestimated malignancy rate of 2.5% was found for subsolid nodules within 
category 2 (malignancy rate in Lung-RADS 1-2 %). The slight statistical underesti-
mation of nonsolid nodules appears to be clinically less relevant given the 
generally indolent character of these lesions and the fact that the management 
difference only refers to the time interval of low-dose follow-up CT scans. Instead, 
an option to also upgrade category 2 lesions to category 4X in future Lung-RADS 
editions might be considered, given the increasing knowledge about suspicious 
morphological findings beyond diameter alone.
 On the other hand, category 4B subsolid nodules showed a malignancy rate of 
23.9%, matching the malignancy rate in Lung-RADS (> 15%). However, interestingly 
we found that one-third of the falsely upgraded benign lesions were transient. 
Thus, in this category integration of short-term follow-up to confirm persistence 
would prevent unnecessary invasive workup in 4B subsolid nodules.
Part II. Mathematical prediction models and automatic 
classification of subsolid nodules
Several guidelines refer to the Brock prediction model to assess malignancy risk 
for a nodule. However, like other prediction models, the Brock model was developed 
and validated on data sets containing mainly solid nodules. Moreover, the Brock 
model does not contain any information of follow-up scans. Thus in chapter 4 we 
validated the Brock model on a large data set of subsolid nodules and assessed the 
effect of including growth after 1 year as a predictor of the model. For this study 
all participants from the National Lung Screening Trial (NLST) with a subsolid 
nodule on baseline and one year follow-up scan were included. Applying the 
calculator to the baseline subsolid nodules yielded an AUC of 0.893 (95% CI 
0.871-0.915) for predicting lung cancer. Of the selected subsolid nodules, 1236 
nodules (57%) were found to be persistent after one-year follow-up. Applying the 
calculator to persistent nodules only yielded an AUC of 0.872 (95% CI 0.843-0.901). 
Adding growth improved the AUC significantly to 0.915 (95% CI 0.891-0.939). We 
concluded that the Brock model yields a high nevertheless somewhat lower 
performance for discriminating benign from malignant subsolid nodules alone 
compared to a study group predominantly consisting of solid nodules. More 
importantly, we showed that lung cancer risk estimation in persistent subsolid 
nodules over a follow-up of 6.5 years can be significantly improved by adding 
short-term growth after one year to a risk calculator. Thus growth, though very 
small, adds important information. These results can be used in the future for a 
more personalized follow-up management, potentially reducing costs and risks of 
long-term follow-up.
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Nodule type is one of the parameters in the Brock model, and a main factor in all 
current guidelines for determining the type of workup. However, we know from 
previous studies that the inter-reader variability in assessing nodule type is high 
among radiologists. Therefore an automatic and more generalized way of 
classifying nodule types would help in managing the workup of pulmonary 
nodules. In chapter 5 we present a deep learning system based on multi-stream 
multi-scale convolutional neural networks, which automatically classifies all 
nodule types relevant for nodule workup. The system processes raw CT data 
containing a nodule without the need for any additional information such as 
nodule segmentation or nodule size and learns a representation of 3D data by 
analyzing an arbitrary number of 2D views of a given nodule. The deep learning 
system was trained with data from the Italian MILD screening trial and validated 
on an independent set of data from the Danish Lung Cancer Screening Trial. We 
showed that the proposed deep learning system achieves performances at 
classifying nodule type that surpasses the one of classical machine learning 
approaches and is within the inter-observer variability among four experienced 
human observers.
Part III. Risk prediction models for pulmonary nodules:  
transition from screening to clinical setting
Much attention has been paid to subsolid nodules in a screening setting, including 
the development of a reliable mathematical prediction model for screen-detected 
nodules such as the Brock model. However, the Brock model was developed and 
validated on a lung cancer screening data base. Nevertheless, the British Thoracic 
Society recommends the Brock model as an initial risk calculator in their workup 
recommendation also for incidental nodules in clinical patients. The question is 
whether the Brock model does work similarly well on a clinical population.
 Thus, in chapter 6 we aimed to evaluate the Brock malignancy risk model on 
routine clinical patients from two academic centers. In these two academic 
centers within the same country (A and B), we established a list of all subjects 
aged 40 years or older that received a chest CT scan between 2004 and 2012. This 
resulted in 16,850 unique subjects for center A and 23,454 for center B. The Brock 
model was separately validated on both data sets, including an analysis with 
nodule size as sole input factor. ROC analysis using areas under the curve (AUCs) 
were calculated and compared. After the annotation process final analysis 
included 177 malignant and 695 benign nodules for center A, and 264 malignant 
and 710 benign nodules for center B. High AUCs exceeding 0.90 were found for the 
full Brock model in our daily routine clinical cohort. Significantly lower values 
were found when using size only (AUCs of 0.87). At the optimum of the model, 
sensitivity and specificity were 84-86% and 80%, with PPV and NPV of 10-14% and 
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99%, respectively. At a risk threshold cut-off of 10%, as suggested by the British 
Society guidelines to trigger intensified diagnostic workup, sensitivity was 
75-81%, with very high negative predictive values of 99%. Thus our results confirm 
that also outside screening setting, the Brock model shows comparably high 
predictive accuracy as a lung cancer risk calculator justifying the use of the Brock 
model also in incidentally seen clinical nodules as suggested by the BTS guidelines 
and offering high potential for improving and individualizing nodule management 
also in a clinical setting.
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Samenvatting
Longkanker is de meest dodelijke vorm van kanker in de wereld en het probleem 
neemt nog steeds in omvang toe. De overlevingskans is afhankelijk van het 
stadium waarin de longkanker wordt ontdekt. De vroege, maar ook latere stadia 
van een van de meest voorkomende vormen van longkanker (adenocarcinoom) 
kunnen op een CT zichtbaar zijn als 'subsolide nodulen'. Subsolide wil zeggen dat 
de gehele of tenminste een deel van de nodule door een sponsachtige groeiwijze 
een relatief lage dichtheid heeft, vergelijkbaar met matglas. Deze subsolide 
nodulen bestaan uit twee vormen: een non-solide (matglas) nodule en partieel 
solide nodule. Een probleem met subsolide nodulen is dat hun biologisch gedrag 
anders is dan dat van de meer gebruikelijke solide nodulen. Ook subsolide nodulen 
die later maligne blijken, zijn vaak indolent met een langzame groei. Richtlijnen 
adviseren jarenlange follow-up om longtitidunale veranderingen op te sporen, 
zoals groei of morfologische veranderingen. Mathematische risicomodellen zouden 
kunnen helpen bij dit proces. In dit proefschrift behandelen we enkele kwesties 
met betrekking tot de karakterisering en risico voorspelling van subsolide 
nodulen door computers en radiologen. Dit zou kunnen leiden tot het optimaliseren 
en personaliseren van het vervolgtraject in patiënten met subsolide nodulen.  
De eerste paar studies in dit proefschrift richten zich op screening datasets, in de 
laatste studie wordt een stap gemaakt naar een grote klinische dataset. Dit proefschrift 
kan onderverdeeld worden in drie delen:
Deel I: visuele beoordeling van subsolide nodule kenmerken  
Deel II:  mathematische risicomodellen en automatische classificatie van subsolide 
nodulen
Deel III: risicomodellen voor nodulen: de stap van screening naar de kliniek
Deel I: visuele beoordeling van subsolide nodule kenmerken
Subsolide nodulen komen minder voor dan solide nodulen en blijken in veel 
gevallen niet- persisterende benigne nodulen te zijn. In hoofdstuk 1 evalueerden 
we in hoeverre radiologen in staat zijn om op basis van visuele interpretatie de 
differentiatie te maken tussen de persisterende en niet-persisterende subsolide 
nodulen. Immers, de differentiatie tussen deze twee zou kunnen leiden tot 
minder (korte termijn) follow-up scans bij patiënten en hierdoor verbetering van 
patiëntenzorg. In dit hoofdstuk lieten wij zien dat de radiologen matig in staat 
waren om deze differentiatie te maken en er waren nauwelijks morfologische 
kenmerken waaruit de differentiatie was te herleiden. We concludeerden daarom 
dat visuele morfologische kenmerken op CT niet genoeg waren om een korte 
termijn follow-up voor subsolide nodulen achterwege te laten.
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In hoofdstuk 2 gingen we een stap verder en keken we naar het gebruik van de 
zogenaamde categorie 4X bij subsolide nodulen in de Lung-RADS richtlijnen. 
Lung-RADS is een bekende richtlijn voor de follow-up management van nodulen 
in screening. In tegensteling tot de andere categorieën in Lung-RADS, is categorie 
4X gebaseerd op het oordeel van de radioloog, waarbij patiënten met een 
Lung-RADS categorie 3 of hoger met zeer verdachte nodulen opgewaardeerd 
kunnen worden naar categorie 4X waardoor ze alsnog een meer invasief vervolg-
onderzoek zouden krijgen. In dit hoofdstuk lieten wij zien dat radiologen heel 
goed bleken te zijn in het uit elkaar halen van verdachte ‘maligne’ subsolide 
nodulen en niet-verdachte nodulen die uiteindelijk benigne bleken te zijn. We 
concludeerden dat de inclusie van deze 4X categorie van toegevoegde waarde is 
voor de follow-up richtlijnen van subsolide nodulen.
 In hoofdstuk 3 keken we naar de laagste (categorie 2) en hoogste categorie 
(categorie 4B) van de Lung-RADS, waar geldt dat hoe groter de nodule, hoe hoger 
de categorie, des te uitgebreider of zelfs invasiever de follow-up is (bijvoorbeeld 
een biopt). Omdat de hoogste categorie kan leiden tot overschatting van nodulen 
en de laagste categorie juist tot onderschatting, hebben we een studie gedaan 
naar deze mogelijke effecten. We concludeerden dat een derde van de nodulen in 
categorie 4B niet-persisterende laesies waren, oftewel op de volgende scan waren 
ze verdwenen. In categorie 4B zou een korte-termijn follow-up dit uitgewezen 
hebben en derhalve een waardevolle aanvulling zijn. In de laagste categorie 
werden laesies wel degelijk onderschat, echter gezien het vaak indolente verloop 
van subsolide nodulen zouden de richtlijnen niet strenger moeten worden, wel 
raden we aan om in de toekomst ook voor deze kleine laesies uit categorie 2 een 
optie te maken voor het upgraden naar categorie 4X. 
Deel II: mathematische risicomodellen en automatische classificatie 
van subsolide nodulen
In hoofdstuk 4 werd het bekende Brock model gevalideerd op een grote set subsolide 
nodulen. Het Brock model is een risicomodel om longkanker te voorspellen in 
longnodulen op basis van een enkele CT scan. Maar gezien het feit dat subsolide 
nodulen vaak langzamer groeien en andere kenmerken hebben, kan dit model 
wellicht verbeterd worden voor subsolide nodulen met behulp van bijvoorbeeld de 
parameter ‘groei’ zoals dat na een follow-up scan bepaald kan worden. Het model 
bleek goed te werken voor subsolide nodulen gevonden bij het eerste CT onderzoek. 
Echter, bij persisterende nodulen gevonden bij de tweede CT scan een jaar later 
bleek deze minder goed te werken. In dit hoofdstuk lieten wij zien dat het includeren 
van groei in de analyse het risicomodel aanzienlijk verbeterde. We concludeerden 
daarom dat groei belangrijke informatie toevoegt aan het model en derhalve in de 
toekomst geïncludeerd zou moeten worden aan de evaluatie van subsolide nodulen.
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In hoofdstuk 5 beschrijven we een systeem dat automatisch verschillende nodule 
typen classificeert (o.a. de subsolide nodulen). Gezien het type van een nodule in 
alle modellen een belangrijke rol speelt in de voorspelling voor longkanker, zou 
het van toegevoegde waarde zijn als deze classificatie automatisch zou kunnen. 
Dit automatische systeem, gebaseerd op deep learning, liet zien dat de classificatie 
van nodule typen net zo goed is als wanneer radiologen dit zouden doen.
Deel III: risicomodellen voor nodulen: de stap van screening  
naar de kliniek
Tot slot werd in hoofdstuk 6 de stap gemaakt naar de klinische populatie. Het 
Brock model is een model dat ontworpen is voor nodulen die bij longkanker 
screening gevonden worden. De klinische populatie heeft echter andere kenmerken 
en het zou kunnen zijn dat dit model niet goed werkt op klinische patiënten. In dit 
hoofdstuk evalueerden we daarom het model op klinische patiënten van twee 
academische centra. Het model bleek goed te werken op beide datasets, en we 
concludeerden dat ook in de dagelijkse kliniek gebruik kan worden gemaakt van 
dit model bij de follow-up van patiënten met longnodulen voor een betere 
voorspelling van de aanwezigheid van longkanker.
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